document incorporate reference incorporate scheringplough corporation proxy statement nual meeting shareholder april iii table content age item business item property item legal proceeding item submission matter vote security holder item market registrant common equity relate stockholder matter item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure management report internal control financial reporting iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item principal accountant fee service item exhibit financial statement schedule report form signature exevi revise form employment agreement exexi severence benefit plan amend restate exl retirement benefit equalization plan exn cash longterm incentive plan exo longterm performance share unit incentive plan exw summary director compensation computation ratio earning fix charge subsidiary consent deloitte touche llp power attorney certification certification certification certification table content item business overview business scheringplough company refer scheringplough corporation subsidiary indicate context trademark indicate capital letter property license promote distribute scheringplough corporation subsidiary relate company predecessor company incorporate new york new jersey stock predecessor company publicly trade scheringplough corporation new jersey corporation incorporate schering corporation scheringplough global sciencebase health care company lead prescription consumer animal health product internal research collaboration business partner scheringplough discover develop manufacture market advanced drug therapy meet important medical need scheringplough vision earn trust physician patient customer shareholder serve world scheringplough worldwide headquarters kenilworth web site wwwscheringploughcom april board director name fred hassan new chairman board chief executive officer scheringplough corporation leadership new leadership team recruit establish eightyear action agenda plan direct goal stabilize repair turn scheringplough produce longterm value shareholder new management team reorganize business manage geographic line primary segment restofworld business organize product currently major product segment prescription pharmaceutical consumer health care animal health principal product segment follow prescription pharmaceutical organize category follow primary care include allergy respiratory clarinex nasonex foradil aerolizer antibiotic avelox cipro dermatological elocon erectile dysfunction levitra copromoted glaxosmithkline plc specialty care include antiinfective intron pegintron rebetol antiinflammatorie remicade table content oncology temodar caelyx intron acute coronary care integrilin subutex suboxone cholesterol merck scheringplough joint venture zetia vytorin consumer health care organize category follow overthecounter claritin afrin coricidin ointment correctol drixoral gynelotrimin foot care scholl lotrimin tinactin sun care coppertone bain soleil solarcaine animal health organize category follow livestock banamine nuflor poultry paracox univaxplus companion animal homeagain aquaculture aquaflor slice scheringplough operate primarily prescription pharmaceutical marketplace appropriate scheringplough seek future seek regulatory approval switch prescription product overthecounter otc status mean extend product life cycle way otc marketplace mean maximize return investment discovery development segment information scheringplough reportable segment prescription pharmaceutical consumer health care animal health segment sale profit datum follow consistent scheringplough current management reporting structure establish second quarter prescription pharmaceutical segment discover develop manufacture market human pharmaceutical product consumer health care segment develop manufacture market otc foot care sun care product animal health segment discover develop manufacture market animal health product table content net sale segment nde dece mber dollars million prescription pharmaceutical consumer health care animal health consolidate net sale profit segment de decem dollar million prescription pharmaceutical consumer health care animal health corporate consolidated lossprofit tax corporate include interest income expense foreign exchange gain loss headquarters expense special charge miscellaneous item accounting policy segment report describe summary significant accounting policy include note item financial statement supplementary datum corporate include special charge million include million employee termination cost million asset impairment charge million closure cost primarily related exit small european research development facility note special charge item financial statement supplementary datum additional information estimate charge relate reportable segment follow prescription pharmaceutical million consumer health care million animal health million corporate million corporate include special charge million include million employee termination cost million provision increase litigation reserve million asset impairment charge note special charge item financial statement supplementary datum additional information estimate charge relate reportable segment follow prescription pharmaceutical million consumer health care million animal health million corporate million net sale geographic area dollar millions united states europe canada latin america pacific area asia consolidate net sale table content company subsidiarie country outside single foreign country france italy japan account percent consolidated net sale past year net sale present geographic area company customer locate dollar illion total international sale france italy japan net sale customer dollar millions mckesson corporation amerisourcebergen corporation single customer mckesson corporation amerisourcebergen corporation major pharmaceutical health care product distributor account percent consolidated net sale past year longlive asset geographic location ollar millions united states ireland singapore puerto rico total longlive asset show geographic location primarily property sale product comprise percent company international sale year end december follow internat ional dollar millio remicade clarinex otc claritin nasonex scheringplough net sale include sale vytorin zetia market partnership merck company account joint venture equity method accounting note equity income cholesterol joint venture item financial statement supplementary datum company disaggregate asset segment basis internal management report information present table content research development scheringplough research activity primarily aim discover develop new prescription product enhancement exist prescription product medical commercial significance company sponsor research development expenditure million million million respectively research expenditure represent approximately percent consolidated net sale percent consolidate net sale approximately percent consolidated net sale scheringplough research activity concentrate therapeutic area allergic inflammatory disorder infectious disease oncology cardiovascular disease central nervous system disorder scheringplough substantial effort direct biotechnology immunology research activity include expenditure internal research effort research collaboration partner pharmaceutical compound vary stage development predict compound available commercial sale company product pipeline list significant product development available scheringplough website global operation nonus operation generate majority company profit cash flow nonus activity carry primarily wholly own subsidiary market potential adequate circumstance permit addition scheringplough represent market licensee distribution arrangement currently scheringplough business operation country approximately employee outside nonus operation subject certain risk inherent conduct business overseas risk include possible nationalization expropriation importation limitation pricing reimbursement restriction restrictive governmental action economic destabilization fluctuation foreign currency exchange rate impact scheringplough consolidated financial result additional information global operation item management discussion analysis financial condition result operation segment information describe patent trademark intellectual property right overview intellectual property protection critical scheringplough ability successfully commercialize product innovation scheringplough own apply license right large number patent country relate molecule product product use formulation manufacturing process assurance patent scheringplough seeking grant patent scheringplough grant find valid challenge patent relate particular molecule product use formulation process preclude manufacturer employ alternative process market alternative product formulation successfully compete company patent product outside standard intellectual property protection pharmaceutical vary widely country reasonably strong patent law country currently provide little effective protection invention intellectual property right traderelate aspect intellectual property agreement trip administer world trade organization wto country agree provide nondiscriminatory protection pharmaceutical invention assure adequate effective right available patent owner possible change agreement future diminish delay implementation develop country soon assess company impact commercially change product patent expire patent holder lose effective market exclusivity product result rapid sharp material decline sale patent product particularly table content case innovator company obtain additional commercial benefit manufacture trade secret laterexpire patent process use formulation trademark use marketing exclusivity available pharmaceutical regulatory law scheringplough intellectual property portfolio patent protection certain scheringplough molecule product process use important scheringploughs business financial result company product addition patent compound scheringplough hold patent manufacturing process formulation use extend exclusivity expiration product patent scheringplough subsidiary license right number patent patent application abroad patent patent application relate scheringplough significant product include limitation clarinex intron pegintron nasonex zetia vytorin material importance scheringplough worldwide scheringplough sell major product trademark material aggregate business financial result trademark protection vary world protection continue country long mark country long register registration normally fix renewable term patent challenge hatchwaxman act drug price competition patent term restoration act commonly know hatchwaxman complex set change patent newdrugapproval law hatchwaxman drug approve provide food drug administration fda complete safety efficacy study know complete new drug application nda hatchwaxman authorize fda approve generic version innovative medicine information file abbreviate new drug application anda anda generic manufacturer demonstrate bioequivalence generic version ndaapprove drug safety efficacy absent successful patent challenge fda approve anda innovators patent expire generic manufacturer file anda allege patent list innovators nda invalid infringe allegation commonly know paragraph certification innovator file suit generic manufacturer protect patent ndaliste patent successfully challenge fil paragraph certification entitle day period market exclusivity generic manufacturer recent year generic manufacturer paragraph certification extensively challenge patent wide array innovative pharmaceutical anticipate trend continue employee approximately people employ scheringplough december marketing activity competition prescription drug introduce known physician pharmacist hospitals manage care organization buy group train professional sale representative sell hospital certain manage care organization wholesale distributor retail pharmacist prescription product introduce known journal advertise direct mail advertising distribute sample physicians television radio internet print advertising medium animal health product promote veterinarian distributor animal producer foot care otc sun care product sell wholesale retail drug food chain mass merchandiser outlet promote directly consumer television radio internet print advertising media pharmaceutical industry highly competitive include large company substantially large scheringplough substantial resource research product development advertising table content promotion field sell support numerous domestic international competitor industry principal competitive technique scheringplough product include research development new improve product vary dosage form strength switch prescription product nonprescription status scheringploughs product subject increasingly competitive pricing manage care group institution federal state government entity agency buy group seek price discount rebate governmental pressure dispense generic product significantly reduce sale certain product long protect patent datum exclusivity arrangement fda government regulation overview pharmaceutical company subject extensive regulation number national state local agency particular importance schere plough regulation fda european medicines agency emea ministry health labor welfare mhlw japan fda jurisdiction scheringploughs business administer requirement cover testing approval safety effectiveness manufacturing labeling marketing scheringplough product fda regulate conversion pharmaceutical prescription otc status extent fda requirement andor review affect resource necessary develop new product bring market scheringplough activity outside european union japan subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing scheringplough product regulatory requirement vary country country fda mhlw emea approval obtain product approval product comparable regulatory authority country outside japan european union case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country failure comply governmental regulation result delay release product delay approval new product seizure recall product suspension revocation authority necessary production sale product fine civil criminal sanction scheringplough subject pharmacovigilance reporting requirement country jurisdiction include european union member states requirement differ jurisdiction jurisdiction include requirement report adverse event occur patient particular drug order alert manufacturer drug governmental agency potential problem fda regulation ongoing basis fda regulate facility procedure manufacture pharmaceutical product sale product facility manufacture accordance current good manufacturing practice cgmp establish fda fda periodically inspect scheringplough facility procedure evaluate compliance fda consent decree scheringplough announce reach agreement fda consent decree resolve issue involve scheringploughs compliance cgmp certain manufacturing facility new jersey puerto rico consent decree require scheringplough complete number action include comprehensive cgmp work plan scheringplough manufacturing facility new jersey puerto rico revalidation finish drug product bulk active pharmaceutical ingredient manufacture facility table content information payment decree completion deadline possible payment ramification deadline miss discuss detail note consent decree item financial statement supplementary datum pricing reimbursement regulation international market scheringplough operate environment governmentmandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug enact acrosstheboard price cut method cost control recent year legislative proposal offer congress state legislature effect major change affect health care system state pass legislation federal state legislative administrative proposal possible include price patient reimbursement constraint medicine mandate discount supplemental rebate expansion exist governmental program new patient population restriction access certain product similar issue arise country outside possible predict outcome initiative effect operation cash flow reasonably estimate scheringplough predict net effect medicare prescription drug benefit market sale new medicare drug benefit medicare effect january offer voluntary prescription drug coverage subsidize medicare million medicare beneficiary compete private prescription drug plan pdps medicare advantage plan scheringplough lead drug cover medicare temodar integrilin intron medicare provide payment physician service include prescription drug administer incident physician service beginning medicare drug reimburse manner limit scheringploughs ability offer large price concession large price increase drug scheringplough drug relatively small portion sale medicare population clarinex hepatitis franchise scheringplough experience expand utilization vytorin zetia new drugs scheringplough pipeline great consequence scheringplough legislation impact pricing rebate discount regulation scheringplough subject jurisdiction federal state regulatory enforcement department agency federal trade commission ftc department justice department health human service scheringplough subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy information merck scheringplough cholesterol joint venture company merck inc merck enter separate agreement jointly develop market cholesterol lower drug allergy asthma drug december cholesterol agreement expand include country world japan general company agree collaborative activity agreement operate virtual mode maximum degree possible rely respective infrastructure company agreement generally provide equal sharing development cost copromotion approve product company cholesterol agreement provide company merck jointly develop ezetimibe market zetia asia ezetrol europe oncedaily monotherapy coadministration statin drug table content iii oncedaily fixedcombination tablet ezetimibe simvastatin zocor merck cholesterolmodifye medicine combination medication ezetimibe simvastatin market vytorin inegy international country zetia ezetrol ezetimibe vytorin inegy combination ezetimibesimvastatin approve use launch international market company utilize equity method account joint venture cholesterol agreement provide share net income loss base percentage vary product sale level country market scheringplough receive great share profit zetia sales zetia sale company share profit equally scheringplough allocation joint venture income increase milestone earn partner share joint venture net income loss subject reduction partner fail perform specify minimum number physician detail particular country partner agree annually minimum number physician detail country partner bear cost general sale force commercial overhead marketing joint venture product world canada puerto rico cholesterol agreement provide reimbursement partner physician detail reimburse equal partner physician detail multiply contractual fix fee scheringplough report receipt reimbursement equity income cholesterol joint venture gaap represent reimbursement specific incremental identifiable cost company detail cholesterol product market addition reimbursement physician detail reflective scheringplough joint venture sale force effort scheringplough sale forcerelate infrastructure cost physician detail generally estimate high cost joint venture partner contractually share portion manufacturing cost specifically identify promotion cost include direct consumer advertising direct identifiable pocket promotion agree cost specific service market support market research market expansion specialty sale force physician education program certain specify research development expense generally share equally partner virtual nature joint venture company incur substantial cost sell general administrative cost reflect equity income cholesterol joint venture bear overall cost structure company cost report respective line item statement consolidated operation cholesterol agreement provide jointly own facility product result collaboration manufacture facility own merck company allergy asthma agreement provide development marketing oncedaily fixedcombination tablet contain claritin singulair singulair merck oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january merck schere plough respiratory joint venture report result phase iii clinical trial fixedcombination tablet contain claritin singulair phase iii study demonstrate sufficient add benefit treatment seasonal allergic rhinitis claritin singulair combination tablet approval country remain clinical development raw material raw material essential scheringplough available adequate quantity number potential supplier energy expect available scheringplough sufficient quantity meet operating requirement table content seasonality certain company product particularly allergy suncare category seasonal nature seasonal pattern pronounce effect consolidated operation scheringplough environment date compliance federal state local law discharge material environment protection environment material effect scheringploughs capital expenditure earning competitive position available information scheringplough amendment report file sec available free charge scheringplough website soon reasonably practicable material electronically file sec scheringploughs address world wide web scheringploughcom scheringplough begin practice quarter report available scheringplough website hour filing report file scheringplough sec read copy secs public reference room fifth street washington information operation public reference room obtain call sec sec sec maintain internet site wwwsecgov contain report proxy information statement information issuer file electronically sec item property scheringplough corporate headquarters locate kenilworth new jersey principal research facility locate kenilworth union summit new jersey palo alto california elkhorn nebraska principal manufacturing facility follow location product type kenilworth new jersey pharmaceuti cal consumer product union new jersey pharmaceuticals miami florida pharmaceuticals consumer product omaha nebraska animal health cleveland tennessee consumer products puerto rico pharmaceuticals argentina pharmaceuticals belgium pharmaceutical consumer product canada pharmaceutical consumer product france pharmaceuticals animal health germany animal health ireland pharmaceutical consumer product animal health italy pharmaceutical japan pharmaceuticals consumer product mexico pharmaceutical consumer product singapore pharmaceutical spain pharmaceutical scheringplough announce reach agreement fda enter consent decree resolve issue involve schering plough compliance cgmp certain manufacturing facility new jersey puerto rico refer government regulation section item note consent decree item financial statement supplementary datum additional information consent decree table content aforementione property own lease scheringplough property generally maintain insure good operating condition scheringplough manufacturing facility capacity consider appropriate meet scheringplough need item legal proceeding material pende legal proceeding ordinary routine litigation incidental business scheringplough corporation subsidiary property subject disclose patent matter describe patent trademark intellectual property right business intellectual property protection critical scheringplough ability successfully commercialize product innovation litigation scheringploughs intellectual property right pende initiate party attempt abridge scheringplough right scheringplough protect right patent matter describe potential material effect company scholl freeze away patent july orasure technology file action district court eastern district pennsylvania allege patent infringement scheringplough healthcare product sale scholl freeze away wart removal product complaint seek permanent injunction unspecified damage include treble damage freeze away product launch march net sale product total approximately million investigation massachusetts investigation attorney office district massachusetts investigate broad range company sale marketing clinical trial practice program warrick pharmaceuticals warrick companys generic subsidiary scheringplough disclose connection investigation schere corporation wholly own significant operating subsidiary scheringplough receive letter boston target letter office advise schering corporation include subsidiary division target federal criminal investigation respect area provide remuneration drug sample clinical trial grant item service value manage care organization physician induce purchase schering pharmaceutical product sale misbrande unapproved drug company understand mean drug promote indication approval fda obtain socalle offlabel use submit false pharmaceutical pricing information government purpose calculate rebate require pay medicaid program fail include price product manufacture sell private label arrangement manage care customer price free nominally price good provide customer induce purchase schering product document destruction obstruction justice relate government investigation target define department justice guideline person prosecutor grand jury substantial evidence link commission crime judgment prosecutor putative defendant attorney manual section company implement certain change sale marketing clinical trial practice continue review practice ensure compliance relevant law regulation company cooperate investigation table content information prior increase liability reserve financial statement include relation investigation litigation charge note special charge additional information reserve potential impact outcome litigation background section note legal environmental regulatory matter item financial statement supplementary datum outcome investigation include commencement civil andor criminal proceeding involve imposition substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program discuss background section note legal environmental regulatory matter contain item financial statement supplemental datum company previously record liability approximately million related investigation reasonably possible settlement investigation involve amount materially excess accrual material adverse impact company financial condition cash flow operation require gaap company reasonably estimate potential final resolution company recognize estimate minimum liability company predict timing resolution matter outcomes nitrodur investigation august company receive civil investigative subpoena issue office inspector general department health human service seek document concern company classification nitrodur medicaid rebate purpose company use nominal pricing bundle product sale company cooperate investigation appear subpoena number address pharmaceutical company concern inquiry issue relate payment government rebate consumer product matter department justice antitrust division investigate company consumer product division enter agreement company low commission rate consumer product broker department closed investigation letter date november pricing matter awp investigation company continue respond investigation department health human services department justice certain state industry company practice average wholesale price awp investigation include department justice review merit federal action file private entity behalf district court southern district florida investigation attorney office district massachusett inter alia awp set pharmaceutical company certain drug improperly exceed average price pay dispenser consequence result unlawful inflation certain government drug reimbursement base awp march company receive subpoena massachusetts attorney general office seek document concern use awp pricing andor marketing practice company respond subpoenas attorney general california concern matters company cooperate investigation outcome investigation include imposition substantial fine penalty injunctive administrative remedy prescription access litigation december prescription access litigation project pal bostonbased group form litigate drug company file class action suit federal court massachusetts company september consolidated complaint file court result coordination multidistrict litigation panel federal court awp case country consolidate complaint allege company warrick pharmaceuticals warrick companys generic subsidiary conspire provider defraud consumer report fraudulently high awps prescription medication reimburse medicare thirdparty payer complaint seek declaratory judgment unspecified damage include treble damage include litigation describe prior paragraph lawsuit allege company warrick report inflated awps prescription pharmaceutical cause state federal entity table content thirdparty payer excess reimbursement provider action allege company warrick fail report accurate price medicaid rebate program underpaid rebate state case file state attorney general seek recover behalf citizen state entity locate state excess payment result inflated awps action begin october bring state attorney general private plaintiff nonprofit organization employee benefit fund allege violation federal state law include fraud antitrust racketeer influence corrupt organization act rico claim quarter company warrick group company accelerate discovery track proceeding addition warrick company defendant number lawsuit state court action generally bring states andor political subdivision seek unspecified damage include treble punitive damage security class action litigation february company state press release fda conduct inspection company manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current good manufacturing practice primarily relate production process control procedure day february lawsuit file district court district new jersey company certain name officer allege violation section securities exchange act rule promulgate thereunder additional lawsuit tenor follow complaint consolidate action district court district new jersey lead plaintiff florida state board administration appoint court july october consolidated amend complaint file allege violation describe purport represent class shareholder purchase share company stock february complaint seek compensatory damage behalf class company motion dismiss consolidated amend complaint deny october court certify shareholder class discovery ongoing addition lawsuit describe lawsuit file district court district new jersey lawsuit file new jersey state court company nominal defendant certain officer director director seek damage behalf company include disgorgement trading profit defendant allegedly obtain basis material nonpublic information complaint lawsuit relate issue describe company february press release allege failure disclose material information breach fiduciary duty director federal court lawsuit include allegation relate investigation attorney office eastern district pennsylvania district massachusetts ftcs administrative proceeding company lawsuit state texas warrick companys generic subsidiary lawsuit shareholder derivative action purport assert claim behalf company demand board director decision company pursue claim august plaintiffs new jersey state court shareholder derivative action move dismiss voluntarily complaint action motion grant shareholder derivative action pende district court district new jersey consolidate action early stage january company receive demand letter date december law firm involve derivative action describe behalf shareholder involve derivative action demand board director bring claim behalf company base allegation substantially similar allege derivative action january board director adopt board resolution establish evaluation committee consist director investigate review analyze fact circumstance surround allegation demand letter consolidate amend derivative action complaint describe reserve board authority discretion exercise business judgment respect proper disposition demand committee engage independent outside table content counsel advise issue report finding investigation independent director board late october report determine shareholder demand refuse find liability officer director november board adopt recommendation evaluation committee company defendant number purport nationwide state class action lawsuit plaintiff seek refund purchase price laxative phenylpropanolaminecontaine coughcold remedy ppa product purchase pharmaceutical manufacturer codefendant lawsuit general plaintiff claim purchase pay product know certain defect medical risk attendant use litigation claim relate company ppa product court national class action suit state class action suit deny certification dismiss suit similar application deny class certification new jersey remain statewide class action suit involve company grant september approximately individual lawsuit relate laxative product ppa product recall albuterolvancerilvancenase inhaler pende company seek recovery personal injury death number lawsuit punitive damage claim march company serve putative class action complaint file district court new jersey allege company richard jay kogan resign chairman board november retire chief executive officer president director company april companys employee saving plan plan administrator breach fiduciary obligation certain participant plan company serve second putative class action complaint file court allegation nearly identical complaint file march october consolidated amend complaint file name additional defendant seven current director corporate officer complaint seek damage loss allegedly suffer plan court dismiss complaint june july plaintiff file notice appeal antitrust ftc matter kdur kdur scheringploughs longacte potassium chloride product supplement cardiac patient scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle relate generic version kdur lederle upsher smith file abbreviate new drug application andas april ftc start administrative proceeding scheringplough upshersmith lederle complaint allege anticompetitive effect settlement june administrative law judge oversee case issue decision patent litigation settlement comply law respect dismiss claim company ftc staff appeal decision commission december commission issue opinion reverse decision rule settlement violate antitrust law commission issue cease desist order impose injunctive restraint opinion file march federal court appeal set aside commission rule vacate cease desist order follow commencement ftc administrative proceeding allege class action suit file federal state court behalf direct indirect purchaser kdur scheringplough upshersmith lederle suit allege essentially fact claim violation federal state antitrust law state statutory andor common law cause action suit seek unspecified damage discovery ongoing table content sec inquiry relate litigation september lawsuit file new jersey superior court union county richard jay kogan company outside director allege breach fiduciary duty fraud deceit negligent misrepresentation relate alleged disclosure meeting subject settlement sec enforcement proceeding regulation plaintiff seek imposition constructive trust profit plaintiff allege realize defendant unlawful act plaintiff seek compensatory damage company remove case federal court case remand state court company file motion dismiss pende administrative obligation disclose note consent decree legal environmental regulatory matter item financial statement supplementary datum scheringplough subject obligation consent decree fda corporate integrity agreement potential penalty failure comply obligation tax matter october irs auditor assert company liable additional tax tax year base allegation interest rate swap unrelated party recharacterize loan affiliate company april company receive formal notice deficiency statutory notice irs assert additional federal income tax company receive bill relate matter irs september payment million income tax million interest september company file refund claim tax interest irs december company notify february refund claim deny company believe comply applicable rule regulation intend file suit refund tax interest environmental matter discuss note legal environmental regulatory matter item financial statement supplementary datum superfund site discuss environmental section note consider normal scheringplough business matter false claim act complaint april company receive notice false claim act complaint bring individual purport act behalf government approximately pharmaceutical company district court northern district texas complaint allege pharmaceutical company include scheringplough defraud sale federal governmental agency drug allegedly manufacture manner comply current good manufacturing practice court grant scheringploughs motion dismiss january emea pharmacovigilance matter pharmacovigilance inspection official british french medicine agency conduct request european medicine agency emea deficiency report process identify scheringplough continues work action plan rectify deficiency provide regular update emea company know action emea national authority response finding possible action include inspection demand improvement report system criminal sanction company andor responsible individual change condition marketing authorization company product biopharma contract dispute biopharma srl file claim civil court rome july docket chamber certain scheringplough subsidiary matter relate table content certain contract date november distribution supply agreement biopharma scheringplough subsidiary distribution scheringplough generic product manufacture biopharma hospital pharmacist france july letter agreement biopharma scheringplough subsidiary medipha sante appoint medipha distribute product france biopharma allege scheringplough fulfill duty contract additional information legal proceeding additional information legal proceeding include important financial information find litigation charge discussion note special charge note legal environmental regulatory matter contain item financial statement supplementary datum item management discussion analysis financial condition result operation item submission matter vote security holder applicable executive officer registrant follow information executive officer include accordance iii item corporate officer list officer elect serve year successor shall duly elect current position business experience robert bertolini present position executive vice president partner pricewaterhousecooper chief financial officer richard bowles iii present position senior vice president vice president quality merck company global quality operation ron cheeley present position senior vice president group vice president global compensation benefit pharmacia corporation global human resource carrie cox present position executive vice president president global executive vice president president global prescription business pharmacia pharmaceuticals corporation senior vice president head global business management pharmacia upjohn william creelman present position vice president tax senior tax counsel pfizer vice president tax smithkline beecham douglas gingerella present position vice president controller vice president corporate audits staff vice president corporate audits fred hassan present position chairman chief executive officer president chairman board chief executive officer pharmacia corporation chief executive officer pharmacia corporation chief executive officer pharmacia upjohn thomas kelly present position vice president corporate business development vice president controller raul kohan present position group head global specialty operation president animal health table content current position business experience joseph larosa present position vice president legal affair staff vice president secretary associate general counsel senior legal director legal director ian mcinne present position senior vice president executive vice president supply chain senior vice president global global supply chain supply chain pharmacia corporation kevin moore present position vice president treasurer daniel nichols present position senior vice president tax cecil pickett phd present position vice president president scheringplough research executive vice president discovery research scheringplough research institute institute anne renahan present position vice president corporate audits executive director controller eisai inc thomas sabatino present position executive vice president general counsel senior vice president general counsel baxter international inc vice president general counsel baxter international inc brent saunder present position senior vice president partner pricewaterhousecooper chief risk officer coventry health global compliance care business practice karl salnoske present position vice president chief ceo adaptive trade general manager ibm information officer susan ellen wolf present position corporate secretary position scheringplough law department senior associate general attorney delta airlines counsel vice president officer define rule securities exchange act table content item market registrant common equity relate stockholder matter common share dividend share price datum approximate number holder record set forth item financial statement supplementary datum table provide information respect purchase company common share fourth quarter issuer purchase equity security tot number max imum number share purchase share publicly purchase total number average price pay announce plan plan period share purchase share program programs october hrough october november november december december total october december share include table repurchase pursuant company stock incentive program represent share deliver company option holder payment exercise price tax withholding obligation connection stock option stock award table content item select financial datum million shar figure perc entage operating result net sale lossincome income taxis net loss income net loss income available common shareholder dilute lossearning common share basic lossearning common share research development expense depreciation amortization expense financial position cash flow property net total asset longterm debt shareholder equity capital expenditure financial statistic net loss income percent net sale return average shareholder equity net book value common share datum cash dividend common share cash dividend common share cash dividend prefer share average share outstanding calculate diluted loss earning common share average share outstanding calculate basic loss earning common share common share outstanding yearend include special charge respectively note special charge item financial statement supplementary datum additional information assume conversion prefer share approximately million common share table content item management discussion analysis financial condition result operation executive summary overview company scheringplough company discover develop manufacture market medical therapy treatment enhance human health company market lead consumer brand overthecounter otc foot care sun care market operate global animal health business researchbase pharmaceutical company scheringplough core strategy invest substantial amount fund scientific research goal create important medical commercial value research development activity focus mechanism treat disease high rate failure inherent research result high risk fund invest research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase commercial phase decade highrisk nature research investment financial resource typically come internal source operation cash reserve equitytype capital source new product product acquire acquisition licensing arrangement product company latestage research pipeline respect acquisition license limit opportunity obtain license critical latestage product limited opportunity typically require substantial amount fund company compete opportunitie company far great financial resource company present financial situation challenge company acquire license critical latestage product positive material financial impact past year company experience number negative event strain continue strain company financial resource negative event include limited follow matter enter formal consent decree food drug administration fda agree revalidate manufacturing process certain manufacturing site puerto rico significant increase spending associate manufacturing compliance effort continue completion fda consent decree obligation addition company find necessary discontinue certain old profitable product outsource product switch claritin begin december prescription otc status switch couple private label competition result low average unit sell price product ongoing intense competition company exposure powerful retail purchaser increase market share sale level certain company product fall significantly experience increase competition product compete decline volatile market investigation certain company sale marketing practice attorney office massachusetts pennsylvania company payment total million attorney office eastern district pennsylvania settlement investigation massachusetts investigation continue pose significant financial commercial risk company response matter begin april company appoint new management team formulate begin implement eightyear action agenda stabilize repair turn company company intend avail foreign earning repatriation provision american job creation act act company intend repatriate billion unremitted foreign earning reduce tax rate repatriation fund provide company great financial stability table content current state business past year company earning cash flow decline significantly override cause loss marketing exclusivity company major pharmaceutical product claritin rebetol increase competition hepatitis market sale marketing cost increase need reinv function launch new product need stabilize market share company remain pharmaceutical product company manufacture site operate optimum production level sale declines reduction output relate fda consent decree time overall cost operate manufacturing site significantly increase consent decree compliance activity company continue review carry value asset indication impairment future event decision lead asset impairment andor relate cost company continue pursue core strategy support market new product research development pipeline plan invest sale marketing scientific research historical level level investment sustainable significant increase profit cash flow operation ability company generate profit significant operating cash flow directly predominantly dependent increase profitability company cholesterol franchise include vytorin zetia less extent grow sale profitability base pharmaceutical business product develop acquire new product controlling expense company generate significant operating cash flow ability invest sale marketing research effort historical level negatively impact zetia company novel cholesterol absorption inhibitor vytorin combination zetia zocor mercks statin medication product launch joint venture company merck cholesterolreduction market single large pharmaceutical market world vytorin zetia position market product compete establish cholesterol management product market company financial resource great company financial commitment compete market share merck profit sale vytorin zetia share merck management provide assurance profit nearterm sufficient company maintain core marketing research strategy sufficient level profit cash flow achieve company need evaluate strategic alternative regard examination strategic alternative contract merck vytorin zetia contract centocor inc remicade exhibit respectively company contain provision relate change control define contract provision result aforementioned product acquire merck revert centocor inc regulatory environment company operate government regulatory agency world regulate company discovery development manufacturing marketing effort fda central regulator company business company work fda resolve issue involve company compliance current good manufacturing practice cgmp certain manufacturing site new jersey puerto rico company reach formal agreement fda enter consent decree term consent decree company payment total million agree revalidate manufacturing process site manufacture site remain open period consent decree place significant additional control production release product site include review thirdparty certification production activity thirdparty certification cgmp improvement project result high cost reduce output facility addition company find necessary discontinue certain profitable old product company research development operation negatively impact decree operation share common facility manufacturing operation table content pricing company pharmaceutical product subject competitive pressure manage care organization seek price discount company require provide statutorily define rebate government agency order participate medicaid veterans health care program governmentfunde program international market company operate environment governmentmandate cost containment program recently clinical trial postmarkete surveillance certain market drug industry raise safety concern lead recall withdrawal adverse labeling market product addition situation raise concern prescriber patient relate safety efficacy pharmaceutical product general company continue maintain robust process monitor adverse event relate product world company personnel regular open dialogue fda regulator review product label material regular basis new information know july scheringplough corporation department justice attorney office eastern district pennsylvania announce settlement relate certain company sale marketing practice investigation term settlement subsidiary scheringplough corporation plead guilty single federal criminal charge concern payment manage care customer addition settlement scheringplough corporation enter fiveyear corporate integrity agreement cia failure comply cia result financial penalty settlement affect ability scheringplough corporation participate federal healthcare program discussion operating result net sale consolidate net sale total billion decrease million percent compare consolidated net sale reflect primarily volume decline offset favorable foreign exchange rate impact percent consolidate net sale billion decrease billion percent versus reflect primarily volume decline offset favorable foreign exchange rate impact percent table content net sale year end december follow incr ease dec rease llar illion prescription pharmaceutical remicade clarinex aerius nasonex pegintron temodar integrilin claritin rxa intron rebetol subutex elocon caelyx pharmaceutical consumer health care otcb foot care sun care animal health consolidate net sale certain prior year amount reclassify conform current year presentation meaningful percentage amount show include international sale claritin include otc claritin respectively international net sale remicade treatment rheumatoid arthritis psoriatic arthritis crohns disease ankylose spondylitis million percent million great medical use expand indication european market sale remicade million million percent compare primarily europe increase patient utilization global net sale clarinex market aerius country outside treatment seasonal outdoor allergy yearround indoor allergy million essentially flat versus sale outside increase percent million market share gain continue conversion prescription claritin sale decrease percent million continue contraction prescription antihistamine market follow launch otc claritin brand nonbranded nonsedate antihistamine couple market share decline global net sale clarinex million increase percent compare million reflect continued conversion patient prescription claritin couple launch clarinex international market global net sale nasonex nasal spray oncedaily corticosteroid nasal spray allergy rise percent million primarily international sale growth favorable prior year trade inventory comparison temper decline market share sale nasonex decrease percent versus million change trade inventory level market share decline table content global net sale pegintron powder injection pegylate interferon product treat hepatitis decrease percent million compare ongoing market competition contract market market share pegintron decline reflect entrance competitor new product hepatitis market sale pegintron decrease million percent million compare primarily loss market share global net sale intron injection chronic hepatitis antiviral anticancer indication decrease percent million primarily low demand sale intron million decline percent primarily loss market share global net sale rebetol capsule use combination intron pegintron treat hepatitis decrease percent million launch generic version rebetol april increase price competition outside sale rebetol million decline percent billion primarily loss market share result new brand competition global net sale temodar capsule treat certain type brain tumor increase million percent million increase market penetration sale temodar million increase percent compare million increase market penetration global net sale integrilin injection glycoprotein platelet aggregation inhibitor treatment patient acute coronary syndrome sell scheringplough primarily increase million percent million increase patient utilization sale integrilin million million respectively millennium pharmaceuticals inc millennium company copromotion agreement integrilin millennium notify company intend exercise right agreement assume responsibility consumer service manage care contracting government report physical distribution integrilin result base final assumption agreement early fourth quarter company require cease recording sale integrilin record share copromotion profit alliance revenue currently company anticipate change record sale integrilin impact earning international net sale prescription claritin decrease percent million million continue conversion clarinex global sale prescription claritin billion reflect billion sale prior conversion otc status international net sale subutex tablet treatment opiate addiction increase percent million increase market penetration sale subutex million million subutex vulnerable generic competition future global net sale elocon cream mediumpotency topical steroid increase percent million sale elocon million million generic competition expect affect sale product international sale caelyx treatment ovarian cancer metastatic breast cancer kaposis sarcoma increase percent million reflect adoption metastatic breast cancer indication patient increase cardiac risk sale caelyx increase percent versus million increase patient utilization couple launch metastatic breast cancer indication pharmaceutical net sale include large number low sale volume prescription pharmaceutical product product sell limited market outside multiple source product long protect patent product include treatment respiratory cardiovascular dermatological infectious oncological disease table content global net sale consumer health care product include otc foot care sun care product increase million percent billion net sale foot care product increase million percent primarily strong performance scholl freeze away new wart remover product net sale sun care product increase million percent primarily timing order shipment sale otc claritin million decrease million percent competition brand private label loratadine net sale consumer health care product increase million percent compare primarily increase sale otc claritin follow launch december global net sale animal health product increase percent million sale favorably impact foreign exchange percent global net sale animal health product increase percent favorably impact foreign exchange percent cost expense equity income summary cost expense equity income year end december follow incr ease crease llar illion cost sale net sale sell general administrative net sale research development net sale expense income net net sale special charge net sale equity income cholesterol joint venture meaningful percentage certain prior year amount reclassify conform current year presentation cost sale percentage net sale increase primarily low production volume couple increase spending relate fda consent decree manufacturing compliance spending effort upgrade company global infrastructure absence european losec revenues change product sale mix include sale bayer license product contribute unfavorable comparison company base pharmaceutical business compete decline volatile market sale cost sale base business product direct impact gross margin cost sale percentage net sale increase change product sale mix result loss sale prescription claritin low production volume increase spending company cgmp compliance effort substantially sale cholesterol product include company net sale result operation joint venture reflect equity income impact company gross operating margin sell general administrative expense sga increase percent billion versus billion primarily expansion sale field force high employee relate cost unfavorable impact foreign exchange partially offset low promotional spending ratio sga net sale percent high ratio percent sga expense table content decrease percent billion billion low pharmaceutical business marketing spending low employee relate cost ratio sga net sale percent high ratio percent primarily lower overall sale report research development spending increase percent billion represent percent net sale include million charge conjunction license toyama chemical company ltd toyama garenoxacin quinolone antibiotic currently development generally change spending reflect timing company fund internal research effort research collaboration partner discover develop steady flow innovative product increase expense income net primarily result high net interest expense expense income net include million income relate sale company marketing right suboxone subutex sublingual tablet treatment opioid dependence special charge component special charge follow dollar million litigation charge employee termination cost asset impairment relate charge litigation charge litigation reserve increase million million respectively primarily result investigation companys sale marketing practice employee termination cost august company announce global workforce reduction initiative phase initiative voluntary early retirement program verp program eligible employee december elect early retirement receive enhance retirement benefit approximately employee elect retire program approximately employee retire yearend approximately employee stagger retirement date total cost program approximately million comprise increase pension cost million increase postretirement health care cost million vacation payment million cost relate accelerate vest stock grant million employee stagger retirement date amount recognize charge employee remain service period amount recognize program million million respectively expect recognize million termination cost associate verp total million million respectively asset impairment relate charge company record asset impairment relate charge million million respectively charge relate primarily shutdown small european researchanddevelopment facility table content asset impairment relate charge relate closure manufacturing facility united kingdom writedown production equipment relate product long produce manufacturing site operate fda consent decree writedown drug license sun care trade expect cash flow support carry value summary select special charge follow summarize activity account related employee termination cost asset impairment relate charge empl oyee asset imp airment termination relate cost charge dollar million special charge incur impairment writedown credit retirement benefit plan liability disbursement special charge liability balance december special charge incur impairment writedown credit retirement benefit plan liability disbursement special charge liability balance december equity income cholesterol joint venture global cholesterol franchise sale include sale company cholesterol joint venture merck vytorin zetia total billion million respectively vytorin approve country launch country include july zetia approve country launch international market november company utilize equity method account joint venture share net income base percentage vary product sale level country scheringplough allocation joint venture income increase milestone earn partner bear cost general sale force commercial overhead marketing joint venture product world canada puerto rico joint venture reimburse partner predefine physician detail set annual basis scheringplough report receipt reimbursement equity income gaap represent reimbursement specific incremental identifiable cost company detail cholesterol product market addition reimbursement physician detail reflective scheringplough joint venture sale force effort scheringplough sale forcerelate infrastructure cost physician detail generally estimate high cost joint venture partner contractually share portion manufacturing cost specifically identify promotion cost include directto consumer advertising direct identifiable outofpocket promotion agreedupon cost specific service market support market research market expansion specialty sale force physician education program certain specify research development expense generally share equally partner equity income cholesterol joint venture define total million million respectively table content company recognize milestone merck million million respectively relate approval ezetimibesimvastatin mexico certain european approval zetia amount include equity income certain condition specify merck agreement merck pay additional milestone company total million noted company incur substantial cost sell cost reflect equity income cholesterol joint venture bear entirely company prior venture research development phase company share research development expense million report research development statement consolidated operation research development cost relate joint venture include equity income provision income taxis tax expense million million million respectively tax provision include charge approximately million tax charge million million foreign tax credit relate intend repatriation previously unremitte foreign earning american job creation act act million foreign state taxis valuation allowance approximately million provide certain defer tax asset result change company tax planning strategy trigger opportunity advantage act discussion overall impact act company tax provision include net operating loss nol carryback benefit approximately million net loss income net loss million versus loss million net income billion net loss include tax expense million primarily intend repatriation unremitte foreign earning valuation reserve net defer tax asset net loss reflect high sell general administrative expense associate buildup sales force vytorin launch addition sale representative result bayer licensing agreement pretax special charge million describe result include pretax research development charge million license garenoxacin toyama chemical company ltd net loss include special charge million describe net income include special charge million increase litigation reserve net loss available common shareholder net loss available common shareholder include deduction prefer stock dividend million relate issuance mandatory convertible preferred stock august impact american job creation act american jobs creation act act enact law october provision act effectively reduce tax rate qualifying repatriation fund hold foreignbase subsidiary percent normally repatriation tax rate percent qualify reduce tax rate fund repatriate oneyear period fund qualifying expenditure fund repatriate reduce tax rate limit unremitte foreign earning report company annual report table content company intend repatriate approximately billion act maximum fund qualify reduce tax rate repatriation fund trigger income tax payment approximately million net available tax credit financial reporting purpose tax payment recognize expense repatriate fund act benefit company follow way discuss detail liquidity financial resource section company operation incur significant negative cash flow expect repatriation act provide company great financial stability ability fund cash need intermediate term disclose prior filing company intend fund future cash flow deficit repatriate fund amount nol strategy minimized taxis repatriation fund utilize nol potential benefit able carry forward nol reduce taxable income future act qualifying repatriation reduce tax loss result act company cash necessary fund cash need maintain potential benefit able carry forward nol reduce taxable income future potential future benefit significant dependent company achieve profitability gaap company review provide valuation allowance defer tax asset future benefit company generally establish valuation reserve net defer tax asset fourth quarter change tax planning strategy trigger opportunity advantage act december company approximately billion nol tax purpose available offset future taxable income company general record valuation allowance net defer tax asset company expect additional nols generate congress legislate certain technical correction relate act company nol reduce approximately million stated company intend repatriate approximately billion december company foreignbase subsidiary hold cash shortterm investment total approximately billion exclude billion cash foreignbase subsidiary receive counterparty termination interest rate swap arrangement company terminate additionally foreignbase subsidiary expect generate substantial cash flow available fund plan repatriation liquidity financial resource discussion cash flow operating activity million cash include receipt million tax refund relate carryback nol payment million government tax deficiency relate certain transaction enter payment million settlement agreement attorney office eastern district pennsylvania operating activity provide approximately million cash include cash flow benefit reduction account receivable follow end sale claritin prescription product include million payment relate fda consent decree operating activity worldwide basis generate insufficient cash fund capital expenditure dividend cash flow deficit particularly pronounce disaggregate geographic basis foreign operation generate cash excess local cash need operation table content cash need excess cash generate operation fund dividend payment vast majority research development cost capital expenditure year prior overall cash need fund primarily operation follow loss marketing exclusivity claritin december profit cash generation decline materially cash requirement include operate cash need capital expenditure litigation tax charge dividend common preferred share approximate billion company borrow fund issue equity security discuss finance operation continue accumulate cash foreignbase subsidiary management expect dividend capital expenditure worldwide basis exceed cash generate operating activity operation continue generate negative cash flow payment litigation investigation increase cash need management expect fund overall cash flow deficit cash investment currently hold foreign subsidiary american job creation act discuss provide company great financial stability ability fund cash need intermediate term total cash cash equivalent shortterm investment total debt approximately billion december company anticipate decline remain positive august company issue mandatory convertible preferred stock note shareholder equity consolidated financial statement receive net proceed billion deducting commission discount underwriting expense proceed reduce shortterm commercial paper borrowing pay settlement amount litigation cost fund operating expense shareholder dividend capital expenditure prefer stock issue company billion shelf registration december million remain register unissue shelf registration borrowing credit facility november company issue billion aggregate principal senior unsecured note billion aggregate principal senior unsecured note proceed offer billion general corporate purpose include repay commercial paper outstanding issuance note rate moodys investor service moodys credit watch negative implication standard poor interest rate payable note subject adjustment rating assign note moodys downgrade respectively interest rate payable series note increase note shortterm borrowing longterm debt commitment consolidated financial statement additional information july moodys lower rating note baa accordingly interest payable note increase basis point effective december december interest rate payable note increase interest rate payable note increase adjustment interest rate payable note increase company interest expense approximately million annually company revolve credit facility total billion facility syndicate major financial institution recently negotiate facility billion fiveyear credit facility facility mature require company maintain total debt total capital ratio percent second credit facility provide million line credit maturity date require company maintain total debt total capital ratio percent time company rate baa moodys bbb facility available general corporate purpose consider support company commercial paper borrowing facility require compensating balance nominal commitment fee pay december fund draw facility table content december shortterm borrowing total billion approximately percent outstanding commercial paper commercial paper rating discuss significantly affect company ability issue rollover outstanding commercial paper borrowing time company believe ability commercial paper issuer company shortterm credit rating moodys andor fitch rating fitch issue rollover outstanding commercial paper time company high shortterm credit rating addition total commercial paper capacity available issuer typically higherrate company company maintain sizable line credit commercial bank cash shortterm investment hold foreignbased subsidiary serve alternative source liquidity support commercial paper program credit rating february downgrade company senior unsecured debt rating time lower company short term corporate credit commercial paper rating company rating outlook remain negative shelf registration amend allow company issue billion debt equity security declare effective sec march assign shelf registration preliminary rating senior unsecured debt preliminary subordinate debt rating bbb september million remain register unissue shelf registration april moodys place company senior unsecured credit rating watchlist possible downgrade base concern relate market share decline litigation risk high degree reliance success vytorin july moodys lower company senior unsecured credit rating baa lower company senior unsecured shelf registration rating pbaa lower company subordinate shelf registration rating pbaa pbaa lower company cumulative noncumulative prefer stock shelf registration rating pbaa pbaa confirm company commercial paper rating remove company watchlist moodys rating outlook company negative borrowing credit facility section discussion impact moodys rating downgrade interest rate payable company long term debt november fitch downgrade company senior unsecured bank loan rating commercial paper rating companys rating outlook remain negative announce downgrade fitch note sale decline company lead product franchise time intron franchise greater anticipate concerned total company growth reliant performance key growth driver zetia remicade near term august fitch affirm company asenior unsecured rating bank loan rating commercial paper rating reiterate negative outlook company credit rating decline impact decline reduce availability commercial paper borrowing increase interest rate company longterm debt discuss company believe repatriation fund american job creation act allow company fund cash need intermediate term financial arrangement contain credit rating downgrade trigger company interest rate swap arrangement effect counterparty bank subject credit rating trigger arrangement utilize long term interest rate swap contract foreignbase subsidiary company bank subsidiary company bank contract equal offset term cover master netting arrangement contract involve foreignbased subsidiary permit subsidiary prepay portion future obligation bank contract involve subsidiary permit bank prepay portion future obligation subsidiary interest pay prepay balance party table content market rate prepayment total billion contract december arrangement originally provide event company fail maintain require minimum credit rating counterparty terminate transaction designate early termination date early month follow date notice terminate sps moodys current credit rating specify minimum date counterparty give company notice terminate december company counterparty mutually agree amend swap contract company counterparty agree phase termination arrangement include repayment prepaid amount base agree schedule schedule termination associate repayment prepaid amount begin later march end later january addition amend agreement month grace period previously apply event counterparty give notice termination result company failure maintain required minimum credit rating extend january event counterparty give company termination notice provision schedule termination associate payment continue accord agree repayment schedule time delivery termination notice january provision original arrangement allow counterparty month notice terminate transaction anniversary transaction november company credit rating moodys eliminate place company accept new credit trigger provide counterparty terminate transaction company fail maintain longterm dollar denominate senior unsecured indebtedness rating bbb baa moodys termination provision later november day date company receive notice terminate company fail meet minimum credit requirement result early termination provision schedule swap termination associate payment continue termination date company option accelerate schedule termination associate payment nominal fee february company foreign base subsidiary subsidiary give notice counterparty terminate arrangement accordingly prepay amount repay respective obligor company repay obligation fund repatriate american job creation act section entitle impact american job creation act table content contractual obligation payment period company know contractual obligation december follow payme nts erio total year year year year dol lars millio longterm debt obligation operating lease obligation purchase obligation advertising contract research contract capital expenditure commitment purchase order record longterm liability total longterm debt obligation include million aggregate principal percent senior unsecured note million aggregate principal percent senior unsecured note note shortterm borrowing longterm debt commitment consolidated financial statement additional information research contract include potential milestone payment payment contingent occurrence certain event table exclude research contract cancelable company penalty open purchase order consist cancelable noncancelable inventory expense item caption include obligation base undiscounted amount estimate payment certain company pension plan hold qualified asset estimate payment company defer compensation plan environmental matter company responsibility environmental cleanup state local federal law include comprehensive environmental response compensation liability act commonly know superfund environmental expenditure base information currently available anticipate material impact company note legal environmental regulatory matter consolidate financial statement additional information additional factor influence operation company pharmaceutical product subject increasingly competitive pricing manage care group institution government agency group seek price discount international market company operate environment governmentmandate costcontainment program market company pharmaceutical manufacturer require provide statutorily define rebate government agency order participate medicaid veterans health care program governmentfunde program government place restriction physician prescription level patient reimbursement emphasize great use generic drug enact acrosstheboard price cut method control cost company unable predict final form time future domestic international governmental health care initiative include passage law permit importation pharmaceutical effect operation cash flow reasonably estimate table content similarly effect operation cash flow decision government entity manage care group group concern formulary pharmaceutical reimbursement policy reasonably estimate company predict net effect medicare prescription drug benefit market sale new medicare drug benefit medicare effect january offer voluntary prescription drug coverage subsidize medicare million medicare beneficiary compete private prescription drug plan pdps medicare advantage plan company lead drug cover medicare temodar integrilin intron medicare provide payment physician service include prescription drug administer incident physician service beginning medicare drug reimburse manner limit scheringploughs ability offer large price concession large price increase drug scheringplough drug relatively small portion sale medicare population clarinex hepatitis franchise company experience expand utilization vytorin zetia new drug company pipeline great consequence company legislation impact pricing rebate discount significant portion net sale major pharmaceutical health care product distributor major retail chain consequently net sale quarterly growth comparison affect fluctuation buy pattern major distributor retail chain trade buyer fluctuation result seasonality pricing wholesaler buying decision factor market pharmaceutical product competitive company operation affect technological advance competitor industry consolidation patent grant competitor new product competitor new information clinical trial market product postmarkete surveillance generic competition company product mature addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product effect operation competitive factor patent dispute predict company launch otc claritin december december compete otc loratadine product launch privatelabel competition introduce company continue market clarinex desloratadine tablets treatment allergic rhinitis combine indication seasonal allergic rhinitis indication perennial allergic rhinitis treatment chronic idiopathic urticaria hive unknown cause ability company capture maintain market share clarinex otc claritin market depend number factor include additional entrant market allergy treatment clinical differentiation clarinex allergy treatment perception extent differentiation marketplace pricing differential otc claritin clarinex allergy treatment generic otc loratadine erosion rate otc claritin clarinex sale entry additional generic otc loratadine product brand secondgeneration antihistamine switch prescription otc status clarinex experience intense competition prescription allergy market prescription allergy market shrink otc switch claritin december additionally company implement new marketing effort address market share performance clarinex switch claritin otc status introduction compete otc loratadine result rapid sharp material decline claritin sale company result operation sale prescription claritin product million percent company consolidated global sale billion percent sale clarinex abroad materially adversely affect presence generic otc loratadine otc claritin light factor describe management believe company december introduction otc claritin introduction compete otc loratadine product december additional entrant generic otc loratadine product market rapid sharp material adverse effect company result operation table content pegintron rebetol combination therapy hepatitis contribute substantially sale less extent fourth quarter compete pegylate interferonbased combination product include brand ribavirin receive regulatory approval major market include overall market share hepatitis franchise decline sharply reflect new market competition addition overall market value contract management believe ability pegintron rebetol combination therapy maintain market share continue adversely affect competition hepatitis marketplace generic form ribavirin enter market april october generic ribavirin approve fda generic form ribavirin compete company rebetol ribavirin capsule prior second half rebetol patent material company business result introduction competitor pegylate interferon introduction generic ribavirin value important company product franchise severely diminish earning cash flow materially negatively impact october merck scheringplough pharmaceutical announce fda approve zetia ezetimibe use statin treatment elevate cholesterol level march company announce ezetimibe ezetrol market europe successfully complete european union mutual recognition procedure mrp completion mrp process member states iceland norway grant national marketing authorization unify labeling ezetrol ezetrol launch international market merck scheringplough partnership develop oncedaily tablet combine ezetimibe simvastatin zocor merck cholesterolmodifye medicine product market vytorin inegy international market ezetimibesimvastatin approve marketing country include germany april mexico march july merck scheringplough pharmaceutical announce fda approve vytorin inegy complete mrp europe october september company announce enter agreement bayer intend enhance company pharmaceutical resource agreement enter company primarily strategic purpose commence october puerto rico company begin marketing selling distribute bayer primary care product include avelox cipro exclusive license agreement company pay bayer royalty excess percent product base sale unfavorable impact company gross margin percentage commence october company assume bayer responsibilitie commercialization activity relate erectile dysfunction medicine levitra bayer copromotion agreement glaxosmithkline plc company report share levitra results alliance revenue additionally term agreement bayer support promotion certain company oncology product key european market define period time japan regulatory approval bayer comarket company cholesterol absorption inhibitor zetia arrangement include right future cholesterol combination product zetia file regulatory authority japan fourth quarter agreement bayer potentially restrict company marketing product compete product strategic alliance result company expect need sublicense right garenoxacin quinolone antibacterial agent company license toyama company explore option regard garenoxacin continue fulfill commitment toyama arrangement include take product regulatory approval table content uncertaintie inherent government regulatory approval process include thing delay approval new product formulation indication affect company operation effect regulatory approval process operation predict company subject jurisdiction national state local regulatory agency subject potential administrative action particular importance fda jurisdiction company business administer requirement cover testing safety effectiveness approval manufacturing labeling marketing company product time time agency include fda require company address manufacturing advertising label regulatory issue note relate company current manufacturing issue failure comply governmental regulation result delay release product seizure recall product suspension revocation authority necessary production sale product discontinuance product fine civil criminal sanction result material adverse effect company financial position result operation additional information government regulation affect future result provide item business annual report additional information cautionary factor affect future result provide caption cautionary factor affect future result cautionary statement private security litigation reform act management discussion analysis operation financial condition include note consent decree consolidated financial statement company announce reach agreement fda consent decree resolve issue involve company compliance current good manufacturing practice certain manufacturing facility new jersey puerto rico district court district new jersey approve enter consent decree term consent decree company agree pay total million government equal installment million installment pay second installment pay previously report company accrue million provision consent decree fourth quarter consent decree require company complete number action event certain action agree consent decree satisfactorily complete time fda assess payment deadline miss consent decree require company develop submit fdas concurrence comprehensive cgmp work plan company manufacture facility new jersey puerto rico cover decree company receive fda concurrence propose cgmp work plan cgmp work plan contain number significant step timely satisfactory completion subject payment business day deadline miss payment exceed million million year payment subject overall cap million connection discussion fda company cgmp work plan pursuant term decree company fda enter letter agreement date april letter agreement company fda agree extend month time period company incur payment describe respect certain significant step date december letter agreement increase yearly overall cap payment describe addition decree require company complete program revalidation finish drug product bulk active pharmaceutical ingredient manufacture covered manufacturing facility company require consent decree complete revalidation program bulk active pharmaceutical ingredient september finish drug december general timely satisfactory completion revalidation subject payment business day deadline miss subject cap describe product schedule revalidation certify validate date validation schedule fda assess payment percent net domestic sale uncertified product table content validation certify payment subject cap describe general product schedule revalidation consent decree certify month schedule date company cease production product certification obtain completion significant step work plan completion revalidation program subject thirdparty expert certification fdas acceptance certification consent decree provide company believe able meet deadline company right show good cause request extension deadline connection cgmp work plan revalidation program guarantee fda grant request company believe significant progress meet obligation consent decree possible company fail complete significant step revalidation prescribe deadline thirdparty expert certify completion significant step revalidation fda disagree expert certification significant step revalidation case possible fda assess payment describe company expense payment assess decree incur addition failure meet term consent decree result delay approval new product seizure recall product suspension revocation authority necessary production sale product fine civil criminal sanction april company receive notice false claim act complaint bring individual purport act behalf government approximately pharmaceutical company district court northern district texas complaint allege pharmaceutical company include company defraud sale federal governmental agency drug allegedly manufacture manner comply current good manufacturing practice company defendant file motion dismiss second amend complaint action april company subject pharmacovigilance reporting requirement country jurisdiction include european union member states requirement differ jurisdiction jurisdiction include requirement report adverse event occur patient particular drug order alert manufacturer drug governmental agency potential problem pharmacovigilance inspection official british french medicine agency conduct request european agency evaluation medicinal product emea deficiency report process identify company take urgent action rectify deficiency quickly possible company know action emea national authority response finding possible action include inspection demand improvement report system criminal sanction company andor responsible individual change condition marketing authorization company product company sell numerous upper respiratory product contain pseudoephedrine pse fdaapprove ingredient relief nasal congestion company annual sale upper respiratory product contain pse total approximately million approximately million product include claritind product drixoral coricidin chlortrimeton product company understand pse illicit manufacture methamphetamine dangerous addictive drug february states canada enact regulation concern sale pse include limit product purchase time require product locate pharmacist counter state goal deter illicitillegal manufacture methamphetamine additional state enact limit quantity pse person possess date regulation material impact company operation financial result table content describe specifically note legal environmental regulatory matter consolidate financial statement price sale marketing program arrangement relate business practice company participant health care industry increase scrutiny federal state regulatory investigative prosecutorial administrative entity entity include department justice attorney office office inspector general department health human service fda federal trade commission ftc state attorney general office health care law certain governmental entity operate include federal state antikickback statute statutory common law false claim law construe broadly court permit government entity exercise significant discretion event governmental entity believe wrongdoing occur institute civil criminal proceeding institute resolve unfavorably subject company substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program company predict investigation affect marketing practice sale result material adverse impact company financial condition cash flow result operation impact recently issue accounting standard november fasb issue statement financial accounting standard sfas inventory cost sfas require abnormal spoilage expense period incur oppose inventoried amortize income inventory usage fix production facility overhead cost allocate normal production level facility sfas effective inventory cost incur annual period begin june company anticipate material impact implementation accounting standard december fasb issue sfas revise share base payment statement require company recognize compensation expense equal fair value sharebase payment grant employee company require implement sfas july recognize compensation sharebase grant july unvested portion sharebase grant prior july restatement previously issue statement allow required company currently evaluate implementation option available relate financial impact sfas critical accounting policy follow accounting policy consider significant change certain judgment assumption inherent policy affect company financial statement revenue recognition rebate discount return provision income taxis impairment intangible asset property account legal regulatory matter revenue recognition company pharmaceutical product sell direct purchaser wholesaler retailer certain health maintenance organization price discount rebate sale pay federal state agency indirect purchaser market participant manage care organization indemnify beneficiary health plan pharmaceutical cost pharmacy benefit manager table content company recognize revenue title risk loss pass purchaser reliable estimate follow determined commercial discount rebate arrangements rebate obligation certain federal state governmental program iii sale return normal course business recognize revenue company estimate record applicable commercial governmental discount rebate sale return expect grant product sell period amount deduct sale period estimate record prior period reevaluate process reliable estimate item company defer recognition revenue revenue recognition new product base specific fact circumstance include estimate acceptance rate establish product similar marketing characteristic absent ability reliable estimate rebate discount return company defer revenue recognition product discount grant base term arrangement direct indirect market participant market condition include price charge competitor rebate estimate base sale term historical experience trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler thirdparty sellthrough market research datum internally generate information datum information provide purchaser obtain party subject inherent limitation accuracy validity sale return generally estimate record base historical sale return information analysis recent wholesale purchase information consideration stocking level wholesaler forecast demand amount product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze formulation accrual company enter agreement major pharmaceutical wholesaler agreement deal number commercial issue product return time payment processing chargeback quantity inventory hold wholesaler respect quantity inventory hold wholesaler agreement provide financial disincentive wholesaler acquire quantity product excess necessary meet current patient demand use monitoring note agreement company expect avoid situation company shipment product reflective current demand rebate discount return rebate accrual federal state governmental program million december million december commercial discount rebate accrual million december million december respectively rebate accrual establish period relate revenue recognize result reduction sale establishment liability include accrue liability case governmental rebate program company payment involve interpretation relevant statute regulation interpretation subject challenge change interpretive guidance governmental authority result challenge change affect estimate governmental rebate amount ultimately sufficient satisfy company obligation additional information governmental inquiry focus calculation rebate contain note legal environmental regulatory matter consolidate financial statement addition possible result governmental challenge change interpretive guidance actual rebate materially exceed amount accrue table content follow summarize activity account relate accrued rebate sale return discount year ded december dol lars millions accrue rebate return discount begin period provision rebate payment provision return return provision discount discount grant accrue rebate return discount end period management make estimate use assumption record accrual actual amount pay current period consistent previously estimate provision income taxis december taxis provide approximately billion undistributed earning foreign subsidiary consider impact american job creation act certain asset associate earning repatriate additional tax provision necessary tax contingency record address potential exposure involve tax position take challenge tax authority potential exposure result vary application statute rule regulation interpretation include intercompany term crossborder agreement affiliate management believe intercompany term base sound economic fact circumstance utilization cash hold foreign subsidiary investment property company estimate accrual tax contingency contain assumption base past experience judgment potential action tax jurisdiction reasonably possible ultimate resolution tax matter materially great amount accrue company record tax valuation allowance reduce defer tax asset likely realize company consider ongoing prudent feasible tax planning strategy assess need valuation allowance event company determine able realize portion net defer tax asset adjustment defer tax asset increase income period determination likewise company subsequently determine able realize portion net defer tax asset future adjustment defer tax asset charge income period determination impairment intangible asset property intangible asset represent capitalize cost purchase goodwill patent license form intellectual property total million december annual amortization expense year estimate approximately million year base intangible asset record december value asset subject continue scientific medical table content marketplace uncertainty example market pharmaceutical product withdraw market safety reason marketing product occur pronounce warning amount capitalize product need reduce impairment event give rise impairment inherent risk pharmaceutical industry predict management regularly review intangible asset possible impairment company manufacturing site operate optimum level sale declines reduction output relate fda consent decree time overall cost operating manufacturing site increase consent decree compliance activity impact material increase manufacturing cost company continue review carry value asset indication impairment future event decision lead asset impairment andor relate cost account legal regulatory matter management judgment estimate require account legal regulatory matter particular company recognize estimate minimum liability connection certain government investigation sale marketing activity ultimate resolution matter involve amount materially excess amount accrue material adverse impact company financial condition cash flow operation note legal environmental regulatory matter consolidate financial statement market risk disclosure company expose market risk primarily change foreign currency exchange rate less extent interest rate equity price follow describe nature risk foreign currency exchange risk company subsidiary country sale outside account approximately percent global sale virtually sale denominate currency local country company report profit cash flow expose change exchange rate date management deem cost effective engage formulabase program hedge profit cash flow foreign operation derivative financial instrument companys foreign subsidiary purchase significant quantity inventory payable dollar manage level inventory relate payable rate inventory turnover provide level protection adverse change exchange rate risk adverse exchange rate change mitigate fact company foreign operation widespread addition point time company foreign subsidiary hold financial asset liability denominate currency dollar financial asset liability consist primarily shortterm thirdparty intercompany receivables payable change exchange rate affect financial asset liability gain loss arise translation affect net income occasion company derivative hedge specific shortterm risk situation involve foreign currency exposure derivative transaction material interest rate equity price risk financial asset expose change interest rate andor equity price debt equity security hold nonqualified trust employee benefit asset total million december longterm nature liability trust asset fund company exposure market risk deem low financial obligation expose variability interest expense longterm shortterm borrowing company maintain cash cash equivalent portfolio excess borrowing table content accordingly company mitigate exposure change interest rate relate financial obligation company longterm debt outstanding percent decrease interest rate change fair value debt million company expect refund debt disclosure notice cautionary factor affect future result cautionary statement private security litigation reform act management discussion analysis financial condition result operation section report write report oral statement time time company contain forwardlooke statement mean security litigation reform act forwardlooke statement relate expectation forecast future event use word anticipate believe estimate expect forecast project intend plan potential word term similar meaning connection discussion potential future event circumstance future operate financial performance identify forwardlooke statement fact relate strictly historical current fact particular forwardlooking statement include statement relate future action ability access capital market prospective product status product approval future performance result current anticipate product sale effort development program estimate rebate discount return expense program reduce expense cost saving reduction work force outcome contingency litigation investigation growth strategy financial result forwardlooke statement publication turn wrong actual result vary materially guarantee scheringplough financial operational performance performance scheringplough stock scheringplough assume obligation update forwardlooke statement factor cause actual result differ scheringplough forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know possible predict identify factor include follow significant portion net sale major pharmaceutical health care product distributor major retail chain consequently net sale quarterly growth comparison affect fluctuation buy pattern major distributor retail chain trade buyer fluctuation result seasonality pricing wholesaler buying decision factor competitive factor include technological advance attain competitor patent grant competitor new product competitor come market new indication competitive product new exist generic prescription andor otc product compete product schere plough merck scheringplough pharmaceutical joint venture competition otc statin like approve use impact cholesterol reduction market know increase pricing pressure abroad manage care organization institution government agency program development consolidation customer increase pricing pressure result customer great influence prescription decision formulary decision policy potential impact medicare prescription drug improvement modernization act possible legislation regulatory action affect thing pharmaceutical pricing reimbursement include medicaid medicare involuntary approval prescription medicine overthe counter use health care reform initiatives drug importation table content legislation legislation regulation market outside affect product pricing reimbursement access law regulation relate trade antitrust monetary fiscal policy taxis price control possible nationalization patent position highly uncertain patent dispute unusual adverse result patent dispute preclude commercialization product negatively impact sale exist product result injunctive relief payment financial remedy uncertaintie fda approval process regulatory approval review process country include limitation delay approval new product failure meet current good manufacturing practice establish fda governmental authority result delay approval product release product seizure recall product suspension revocation authority necessary production sale product fine civil criminal sanction resolution manufacturing issue fda discuss scheringplough subject substantial risk uncertaintie risk uncertainty include time scope duration resolution manufacturing issue depend ability schere plough assure fda quality reliability manufacturing system control extent remedial prospective obligation undertake scheringplough difficulty product development pharmaceutical product development highly uncertain product appear promise development fail reach market numerous reason found ineffective harmful effect clinical preclinical testing fail receive necessary regulatory approval turn economically feasible manufacturing cost factor precluded commercialization proprietary right postmarkete issue product approve market clinical trial market product postmarkete surveillance raise efficacy safety concern scientifically justify new information lead recall withdrawal adverse labeling market product negatively impact sale concern prescriber patient relate safety efficacy scheringplough product company product pharmaceutical product generally negatively impact sale major product claritin clarinex intron pegintron rebetol capsules remicade temodar nasonex account material portion scheringplough revenue major product subject problem loss patent protection otc availability company product competitive product disclose claritin current potential otc competition previously unknown effect new effective treatment introduce generic availability competitive product product discontinue reason impact revenue significant information important new product zetia vytorin important product pipeline impact future revenue sale vytorin negatively impact sale zetia unfavorable outcome government local federal domestic international investigation litigation product pricing product liability claim litigation environmental concern preclude commercialization product negatively affect profitability exist product materially adversely impact scheringplough financial condition result operation contain condition impact business operation exclusion government reimbursement program economic factor scheringplough control include change inflation interest rate foreign currency exchange rate table content instability disruption destruction significant geographic region location manufacture facility distribution facility customer regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease change tax law include change relate taxation foreign earning change account auditing standard promulgate american institute certify public accountant financial accounting standard board sec public company accounting oversight board require significant change scheringplough accounting practice detail discussion risk uncertainty scheringplough past future sec report filing item quantitative qualitative disclosure market risk market risk disclosure set forth item management discussion analysis financial condition result operation table content item financial statement supplementary datum index financial statement statement consolidated operation year end december statement consolidated cash flow year end december consolidated balance sheet december statement consolidated shareholder equity year end december note consolidated financial statement report independent register public accounting firm table content scheringplough corporation subsidiary statement consolidated operation ear nded ecemb amount million share figure net sale cost sale sell general administrative research development expense income net special charge equity income cholesterol joint venture lossincome income taxis income tax expense net lossincome prefer stock dividend net lossincome available common shareholder dilute lossearning common share basic lossearning common share accompany note integral consolidated financial statement table content scheringplough corporation subsidiary statement consolidated cash flow ar nde december amount million operating activity net lossincome adjustment reconcile net lossincome net cash provide operating activity tax refund loss carryback payment additional tax special charge depreciation amortization change asset liability account receivable inventory prepaid expense asset account payable liability income taxis payable net cash provide operating activity invest activity capital expenditure disposition property equipment proceed transfer license purchase investment reduction investment net net cash investing activity financing activity cash dividend pay common shareholder cash dividend pay prefer shareholder proceed prefer stock issuance net net change shortterm borrowing issuance longterm debt reduction longterm debt net net cash provide financing activity effect exchange rate cash cash equivalent net increase cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement table content scheringplough corporation subsidiary consolidate balance sheet decem ber amount million share figure asset current asset cash cash equivalent shortterm investment account receivable allowance inventory defer income taxis prepaid expense current asset total current asset property cost land building improvement equipment construction progress total accumulate depreciation property net goodwill intangible asset net asset total asset liability shareholder equity current liability account payable shortterm borrowing current portion longterm debt foreign state income taxis accrue compensation accrue liability total current liability longterm liability longterm debt defer income taxis longterm liability total longterm liability commitment contingent liability note shareholder equity mandatory convertible preferred share par value issue share face value common share authorize share par value issue paidin capital retain earning accumulate comprehensive income total treasury share cost total shareholder equity total liability shareholder equity accompany note integral consolidated financial statement table content scheringplough corporation subsidiary statement consolidated shareholder equity accu mulate mandatory total convertible compre share prefer common paidin retain treasury hensive holder amount million share share capital earning share income equity balance january comprehensive income net income foreign currency translation minimum pension liability net tax realize gain reclassify income net tax total comprehensive income cash dividend common share stock incentive plan balance december comprehensive income net loss foreign currency translation minimum pension liability net tax unrealized gain investment available sale net tax total comprehensive income loss cash dividend common share stock incentive plan balance december comprehensive income net loss foreign currency translation minimum pension liability unrealize gain investment available sale total comprehensive income loss issuance preferred stock cash dividend common share dividend preferred share stock incentive plan balance december accompanying note integral consolidated financial statement table content note consolidated financial statement dollar million share figure summary significant accounting policy principle consolidation consolidated financial statement include scheringplough corporation subsidiary company intercompany balance transaction eliminate certain prior year amount reclassify conform current year presentation use estimate preparation financial statement conformity generally accept accounting principle require management estimate use assumption affect certain report amount disclosure actual amount differ equity method accounting company account interest merck inc merck joint venture equity method accounting company significant influence operate financial policy accordingly company share earning merck joint venture include consolidated net lossincome revenue sale vytorin zetia recognize joint venture title risk loss pass customer equity income joint venture exclude profit arise transaction company joint venture time underlying profit realize joint venture transaction party company merck note equity income cholesterol joint venture information joint venture cash cash equivalent cash cash equivalent include operate cash highly liquid investment generally original maturity month include cash cash equivalent approximately restrict cash december respectively investment investment carry market value classify availableforsale inventory inventory value low cost market cost determine lastin firstout lifo method substantial portion inventory locate cost inventory determine firstin firstout method fifo depreciation property equipment depreciation provide estimate useful life property generally use straightline method useful life property follow asset category yea building build improvement equipment depreciation expense respectively company review carry value property equipment indication impairment accordance statement financial accounting standard sfas accounting impairment disposal longlive asset foreign currency translation net asset company foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation adjustment account include comprehensive income remain foreign subsidiary nonmonetary asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income table content note consolidated financial statement continue exchange gain loss arise translate intercompany balance longterm investment nature record foreign currency translation adjustment account exchange gain loss include income accumulate comprehensive income accumulate comprehensive income primarily consist accumulate foreign currency translation adjustment account unrealize gain loss security classify available sale minimum pension liability adjustment component accumulate comprehensive income december accumulate foreign currency translation minimum pension liability net tax accumulate unrealized gain loss investment available sale net tax total gross unrealized pretax gain investment respectively unrealize loss immaterial revenue recognition company pharmaceutical product sell direct purchaser wholesaler retailer certain health maintenance organization price discount rebate sale pay federal state agency indirect purchaser market participant manage care organization indemnify beneficiary health plan pharmaceutical cost pharmacy benefit manager company recognize revenue title risk loss pass purchaser reliable estimate follow determined commercial discount rebate arrangements rebate obligation certain federal state governmental program iii sale return normal course business recognize revenue company estimate record applicable commercial governmental discount rebate sale return expect grant product sell period amount deduct sale period estimate record prior period reevaluate process reliable estimate item company defer recognition revenue earning common share diluted loss common share exclude effect share issuable defer stock unit exercise stock option impact conversion mandatory convertible preferred share include security earning share calculation antidilutive result low loss share diluted loss common share exclude effect share issuable defer stock unit exercise stock option include security antidilutive diluted earning common share compute divide income sum weightedaverage number common share outstanding plus dilutive effect share issuable defer stock unit exercise stock option period present basic earning common share compute dividing incomeloss available common shareholder weightedaverage number common share outstanding table content note consolidated financial statement continue share calculate basic diluted earning common share reconcile follow year end december share million average share outstanding basic earning share dilutive effect option defer stock unit average share outstanding diluted earning share equivalent million million million common share issuable company stock incentive plan exclude computation dilute earning share december respectively effect antidilutive addition million common share issuable conversion company mandatory convertible preferred stock exclude computation dilute loss share effect antidilutive goodwill intangible asset sfas goodwill intangible asset require intangible asset acquire individually group asset initially recognize measure base fair value intangible finite life amortize useful life intangible indefinite life include goodwill amortize company evaluate goodwill impairment fair valuebase test goodwill determine impaired write estimate fair value company goodwill primarily related animal health business component intangible asset net follow december gross gross carrying accumulate carry accumulate amortization net amortization net patent license trademark total intangible asset intangible asset amortize straightline method respective useful life residual value intangible asset estimate zero company record intangible asset relate license copromotion agreement relate levitra avelox amount amortize effective useful life agreement range seven year net carrying patent license reduce approximately result bristolmyer squibbs reacquisition copromotion right tequin company pay patent licensing right cost amortize approximately year amortization expense relate intangible asset respectively intangible asset review determine recoverability compare carry value expect undiscounted future cash flow event circumstance warrant review accounting stockbase compensation currently company account stock compensation arrangement intrinsic value method stockbase employee compensation cost reflect net lossincome company defer stock unit stock option grant plan exercise price equal market value underlie common stock date table content note consolidated financial statement continue grant company defer stock unit stock option issue company stock incentive plan note december financial accounting standard board fasb issue sfas revise share base payment statement require company recognize compensation expense equal fair value sharebase payment grant employee company require implement sfas july recognize compensation sharebase grant july unvested portion sharebase grant prior july restatement previously issue statement allow required company currently evaluate implementation option relate financial impact available sfas follow table reconcile net lossincome available common shareholder basicdilute lossearning common share report pro forma net lossincome available common shareholder basicdilute lossearning common share company expense grantdate fair value stock option defer stock unit permit sfas accounting stockbase compensation net lossincome available common shareholder report add expense include report net income defer stock unit net tax deduct pro forma expense stock option defer stock unit charge net income net tax pro forma net lossincome available common shareholder fair value method diluted lossearning common share dilute lossearning common share report pro forma diluted lossearning common share fair value method basic lossearning common share basic lossearning common share report pro forma basic lossearning common share fair value method weightedaverage fair value option grant respectively fair value estimate blackschole optionprice model base follow assumption dividend yield volatility riskfree interest rate expect term option year table content note consolidated financial statement continue special charge component special charge year end december follow litigation charge employee termination cost asset impairment relate charge litigation charge litigation reserve increase respectively primarily result investigation companys sale marketing practice note additional information employee termination cost august company announce global workforce reduction initiative phase initiative voluntary early retirement program verp program eligible employee december elect early retirement receive enhance retirement benefit approximately employee elect retire program approximately employee retire yearend approximately employee stagger retirement date total cost program approximately comprise increase pension cost increase postretirement health care cost vacation payment cost related accelerate vest stock grant employee stagger retirement date amount recognize charge employee remain service period delay expense recognition follow guidance sfas accounting cost associate exit disposal activity amount recognize relate program year end december respectively termination cost associate verp total respectively asset impairment relate charge asset impairment charge recognize accordance sfas goodwill intangible asset sfas accounting impairment disposal longlive asset year end december company recognize asset impairment charge base discount cash flow charge relate primarily shutdown small european researchanddevelopment facility year end december company recognize asset impairment charge relate follow asset impairment charge total recognize base discount cash flow analysis relate facility equipment company manufacture site asset impairment charge base discount cash flow recognize related intangible asset license cancer therapy drug sell country outside impairment charge relate trade company highend sun care brand recognize base discount cash flow table content note consolidated financial statement continue summary select special charge follow summarize activity account related employee termination cost asset impairment charge ass employee impairment termination relate cost charge special charge incur impairment writedown credit retirement benefit plan liability disbursement special charge liability balance december special charge incur impairment writedown credit retirement benefit plan liability disbursement special charge liability balance december balance december represent distribution yearend equity income cholesterol joint venture company merck enter separate agreement jointly develop market cholesterol lower drug allergyasthma drug december cholesterol agreement expand include country world japan general company agree collaborative activity agreement operate virtual mode maximum degree possible rely respective infrastructure company agreement generally provide equal sharing research development cost copromotion approve product company cholesterol agreement provide company merck jointly develop ezetimibe market zetia asia ezetrol europe oncedaily monotherapy coadministration statin drug iii oncedaily fixedcombination tablet ezetimibe simvastatin zocor merck cholesterolmodifye medicine combination medication ezetimibesimvastatin market vytorin inegy international country zetia ezetrol ezetimibe vytorin inegy combination ezetimibesimvastatin approve use launch international market company utilize equity method account joint venture cholesterol agreement provide share net incomeloss base percentage vary product sale level country market scheringplough receive great share profit zetia sales zetia sale company share profit equally scheringplough allocation joint venture income increase milestone earn partner share joint venture net incomeloss subject reduction partner fail perform specify minimum number physician detail particular country partner agree annually minimum number physician detail country table content note consolidated financial statement continue partner bear cost general sale force commercial overhead marketing joint venture product world canada puerto rico cholesterol agreement provide reimbursement partner physician detail set annual basis reimburse equal partner physician detail multiply contractual fix fee scheringplough report receipt reimbursement equity income cholesterol joint venture gaap represent reimbursement specific incremental identifiable cost company detail cholesterol product market addition reimbursement physician detail reflective scheringplough joint venture sale force effort scheringplough sale forcerelate infrastructure cost physician detail generally estimate high cost joint venture partner contractually share portion manufacturing cost specifically identify promotion cost include directto consumer advertising direct identifiable outofpocket promotion agree cost specific service market support market research market expansion specialty sale force physician education program certain specify research development expense generally share equally partner follow information provide summary component company equity income cholesterol joint venture year end december unau dite scheringploughs share net incomeloss include milestone respectively reimbursement scheringplough physician detail elimination intercompany profit net total equity income cholesterol joint venture company earn milestone respectively relate approval ezetimibesimvastatin mexico certain european approval ezetimibe certain condition specify agreement merck pay additional milestone company total equity income joint venture exclude profit arise transaction company joint venture time underlying profit realize joint venture transaction party company merck virtual nature joint venture company incur substantial cost sell general administrative cost reflect equity income cholesterol joint venture bear overall cost structure company cost report respective line item statement consolidated operation cholesterol agreement provide jointly own facility product result joint venture manufacture facility own merck company discuss company account merck scheringplough cholesterol partnership equity method accounting company net sale include sale joint venture prior joint venture research development phase company share research development expense report research development statement consolidated operation allergyasthma agreement provide development marketing oncedaily fixedcombination tablet contain claritin singulair singulair merck oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january merck schere plough respiratory joint venture report result phase iii clinical trial fixedcombination tablet table content note consolidated financial statement continue contain claritin singulair phase iii study demonstrate sufficient add benefit treatment seasonal allergic rhinitis claritin singulair combination tablet approval country remain clinical development expense income net component expense income net follow interest cost incur capitalize construction interest expense interest income foreign exchange gain loss net total net include gain sale marketing right suboxone subutex cash pay interest net amount capitalize respectively income taxis component consolidate lossincome income taxis year end december follow united states foreign total lossincome income taxis component income tax expense benefit year end december follow fede ral sta fore ign tot current deferred total current defer total current defer total table content note consolidated financial statement continue american job creation act act enact october provision act effectively reduce tax rate qualifying repatriation earning hold foreignbase subsidiary percent normally repatriation tax rate percent fourth quarter company decision intend repatriate approximately billion act maximum foreign earning qualify reduce rate intend repatriation earning trigger federal tax payment approximately tax charge foreign tax credit state tax payment approximately amount reflect current income tax expense prior act company provide defer taxis undistribute earning foreign subsidiary company intend indefinitely reinv undistributed earning foreign subsidiary company intent indefinitely reinvest undistributed earning foreign subsidiary repatriate act provide defer taxis approximately undistribute foreign earning determine tax liability arise earning remit practicable depend number factor include earning distribute operation generate taxable profit loss company generate approximately net operating loss nol tax purpose approximately nol eligible carryback benefit tax law result benefit company generate approximately nol tax purpose result benefit december nol generate utilize recoup past taxis pay company carryback benefit allow tax law fourth quarter change tax planning strategy trigger company intent repatriate earning act management long able conclude likely realize benefit net defer tax asset general valuation allowance net defer tax asset establish december impact income tax expense provide valuation allowance net defer tax asset difference income taxis base statutory tax rate company income tax expense year end december follow income tax expensebenefit statutory rate increasedecrease taxis result low rate jurisdiction net federal tax repatriate foreign earning act net credit nol tax benefit record provision valuation allowance net defer tax asset nondeductible litigation reserve reserve tax litigation research tax credit state income tax permanent difference net income tax effective tax rate table content note consolidated financial statement continue low rate jurisdiction net primarily attributable certain employment capital investment action take company result income manufacturing activity jurisdiction subject low tax rate december company total defer tax asset respectively defer tax liability respectively reclassification certain amount defer tax asset liability conform current year presentation valuation allowance net defer tax asset establish december valuation allowance record defer tax asset december respectively significant defer tax liability december depreciation difference respectively benefit plan respectively net consolidated income tax paymentsrefund exclusive payment relate tax audits discuss respectively december company federal income tax return audit tax contingency record address potential exposure involve tax position take challenge tax authority potential exposure result vary application statute rule regulation interpretation include intercompany term cross border arrangement affiliate management believe intercompany term base sound economic fact circumstance utilization cash hold foreign subsidiary investment property company estimate accrual tax contingency contain assumption base past experience judgment potential action tax jurisdiction reasonably possible ultimate resolution tax matter materially great accrue october irs auditor assert report company liable additional tax tax year report allege interest rate swap company enter unrelated party recharacterize loan affiliate company april company receive formal notice deficiency statutory notice irs assert additional federal income tax company receive bill relate matter irs september payment income tax interest september company file refund claim tax interest irs december company notify february refund claim deny irs company believe comply applicable rule regulation company intend file suit refund tax interest company exist tax reserve adequate cover abovementione payment product license acquisition company enter collaboration license agreement toyama chemical ltd toyama term agreement company acquire exclusive worldwide right exclude japan korea china develop use sell garenoxacin toyama quinolone antibacterial agent currently development connection execution agreement company incur charge second quarter upfront fee toyama expense report research development year end december statement consolidated operation september company announce enter strategic alliance bayer intend enhance company pharmaceutical resource october puerto rico company begin market sell distribute bayer primary care product include avelox cipro exclusive license agreement company pay bayer substantial royalty product base sale addition company assume bayer responsibilitie commercialization activity relate erectile dysfunction medicine levitra bayer copromotion agreement glaxosmithkline plc company report share levitra results alliance revenue table content note consolidated financial statement continue additionally term agreement bayer support promotion certain company oncology product key european market define period time japan regulatory approval bayer comarket company cholesterol absorption inhibitor zetia ezetimibe arrangement include right future cholesterol combination product agreement bayer provide upfront payment company licensing right levitra avelox company receive record defer revenue relate sale zetia copromotion right bayer defer revenue begin recognize regulatory approval japan certain circumstance zetia receive regulatorymarkete approval japan certain date require repay bayer agreement bayer restrict company market certain product compete avelox cipro levitra result company expect need sublicense right garenoxacin quinolone antibacterial agent company license toyama company explore option regard garenoxacin continue fulfill commitment toyama arrangement include take product regulatory approval february company acquire asset neogenesis pharmaceutical approximately neogenesis apply novel screening chemistry technology discover new drug candidate inventory inventory consist follow december finish product good process raw material supply total inventory inventory value lastin firstout basis comprise approximately percent total inventory december estimate replacement cost total inventory december respectively shortterm borrowing longterm debt commitment shortterm borrowing general shortterm borrowing consist commercial paper issue bank loan note payable commercial paper outstanding december respectively weightedaverage interest rate shortterm borrowing december percent percent respectively credit facility company revolve credit facility total billion facility syndicate major financial institution recently negotiate facility billion fiveyear credit facility facility mature require company maintain total debt total capital ratio percent second credit facility provide line credit maturity date require company maintain total debt total capital ratio percent time company rate baa moodys bbb table content note consolidated financial statement continue facility available general corporate purpose consider support company commercial paper borrowing facility require compensating balance nominal commitment fee pay december fund draw facility addition company foreign subsidiary approximately available unused line credit financial institution december longterm debt november company issue aggregate principal percent senior unsecured note aggregate principal percent senior unsecured note interest payable semiannually net proceed offer issuance note rate moodys investors service inc moodys creditwatch negative implication standard poor rating service interest rate payable note subject adjustment follow subsequent issuance rating assign note moodys change rating set forth interest rate payable series note increase additional interest rate set forth table similarly rate assign note change rating set forth table interest rate payable series note increase additional interest rate set forth table additional interest rate moody rating rating baa bbb baa bbb baa bbb baa event interest rate note increase percent initial coupon rate percent percent respectively moodys subsequently upgrade rating interest rate correspondingly reduce percent percent respectively furthermore interest rate payable particular series note return percent percent respectively rate adjustment provision permanently cease apply follow downgrade moodys respectively moodys raise rating respectively well july moodys lower rating note baa accordingly interest payable note increase basis point effective december effective december interest rate payable note increase percent percent interest rate payable note increase percent percent adjustment interest rate payable note increase company interest expense annually note redeemable company option time redemption price equal great percent principal note sum present value remain schedule payment principal interest discount rate treasury note comparable remain term plus basis point note basis point note shelf registration company shelf registration amend declare effective security exchange commission sec shelf register issuance billion debt equity security subsequently company issue billion face mandatory convertible preferred stock august shelf december principal table content note consolidated financial statement continue security remain register unissue note shareholder equity additional information prefer stock issuance change credit rating february downgrade company senior unsecured debt rating time lower company short term corporate credit commercial paper rating company rating outlook remain negative march assign shelf registration preliminary rating senior unsecured debt preliminary subordinate debt rating bbb april moodys place company senior unsecured credit rating watchlist possible downgrade base concern relate market share decline litigation risk high degree reliance success vytorin july moodys lower company senior unsecured credit rating baa lower company senior unsecured shelf registration rating pbaa lower company subordinate shelf registration rating pbaa pbaa lower company cumulative noncumulative prefer stock shelf registration rating pbaa pbaa confirm company commercial paper rating remove company watchlist moodys rating outlook company negative november fitch rating fitch downgrade company senior unsecured bank loan rating commercial paper rating companys rating outlook remain negative announce downgrade fitch note sale decline company lead product franchise time intron franchise greater anticipate concerned total company growth reliant performance key growth driver zetia remicade near term august fitch affirm company senior unsecured rating bank loan rating commercial paper rating reiterate negative outlook commitment total rent expense amount future annual minimum rental commitment noncancelable operating lease december follow aggregate minimum lease obligation december company commitment total related capital expenditure financial instrument sfas derivative instrument financial hedging activity amend require derivative record balance sheet fair value accounting standard provide effective portion qualify cash flow hedge recognize income hedge item affect income change fair value derivative qualify fair value hedge change fair value hedge risk recognize occur change fair value derivative qualify hedge treatment ineffective portion qualifying hedge recognize income occur risk policy objective company expose market risk primarily change foreign currency exchange rate less extent interest rate equity price change time time company hedge selective foreign currency risk derivative generally management deem cost effective engage formulabase program hedge profit cash flow foreign operation derivative financial instrument companys foreign subsidiary purchase significant table content note consolidated financial statement continue quantity inventory payable dollar manage level inventory relate payable rate inventory turnover provide natural level protection adverse change exchange rate furthermore risk adverse exchange rate change mitigate fact company foreign operation widespread limited basis company hedge selective exposure mitigate interest rate risk company mitigate credit risk derivative instrument deal counterpartie consider financially sound accordingly company anticipate loss nonperformance company enter derivative instrument generate trading profit table present carry value estimate fair value companys financial instrument include derivative financial instrument december estimate fair value determine base market price available dealer quote carry estimate carry estimate value fair value value fair value asset cash cash equivalent shortterm investment longterm investment liabilitie shortterm borrowing current portion longterm debt longterm debt interest rate swap contract longterm investment longterm investment include noncurrent asset primarily consist debt equity security hold nonqualified trust fund long term employee benefit obligation include liability consolidated balance sheet asset fund relate liability longterm investment classify available sale carry fair value realize gain sale security classify available sale proceed sale total respectively realize gain record expense income net interest rate swap contract company interest rate swap arrangement effect counterparty bank subject credit rating trigger arrangement utilize long term interest rate swap contract foreignbase subsidiary company bank subsidiary company bank contract equal offset term cover master netting arrangement contract involve foreignbased subsidiary permit subsidiary prepay portion future obligation bank contract involve subsidiary permit bank prepay portion future obligation subsidiary interest pay prepay balance party market rate prepayment total billion contract december arrangement originally provide event company fail maintain require minimum credit rating counterparty terminate transaction designate early termination table content note consolidated financial statement continue date early month follow date notice terminate sps moodys current credit rating specify minimum march counterparty give company notice terminate december company counterparty mutually agree amend swap contract company counterparty agree phase termination arrangement include repayment prepaid amount base agree schedule schedule termination associate repayment prepaid amount begin later march end later january addition amend agreement month grace period previously apply event counterparty give notice termination result company failure maintain required minimum credit rating extend january event counterparty give company termination notice provision schedule termination associate payment continue accord agree repayment schedule time delivery termination notice january provision original arrangement allow counterparty month notice terminate transaction anniversary transaction november company credit rating moodys eliminate place company accept new credit trigger provide counterparty terminate transaction company fail maintain longterm dollar denominate senior unsecured indebtedness rating bbb baa moodys termination provision later november day date company receive notice terminate company fail meet minimum credit requirement result early termination provision schedule swap termination associate payment continue termination date company option accelerate schedule termination associate payment nominal fee february company foreign base subsidiary subsidiary give notice counterparty terminate arrangement accordingly prepay amount repay respective obligor company repay obligation fund repatriate american job creation act company utilize interest rate swap international cash management strategy notional principal arrangement notional principal arrangement arrangement year term fair value swap liability december interest rate swap relate swap arrangement terminate impact company statement consolidated operation material shareholder equity company authorize share prefer stock consist prefer share designate series junior participate prefer stock prefer share designate mandatory convertible preferred stock prefer share designation determine mandatory convertible preferred stock august company issue share mandatory convertible preferred stock prefer stock face value billion net proceed company billion deducting commission discount underwriting expense proceed general corporate purpose include reduction commercial paper borrowing table content note consolidated financial statement continue mandatory conversion date share september date share automatically convert common share company depend average closing price company common share period immediately precede mandatory conversion date define prospectus prefer shareholder elect convert time prior september minimum conversion ratio common share share prefer stock additionally time prior mandatory conversion date closing price company common share exceed trading day period consecutive trading day company elect cause conversion prefer stock outstanding minimum conversion ratio common share prefer share prefer stock accrue dividend annual rate percent share outstanding dividend cumulative date issuance extent company legally permit pay dividend board director declare dividend payable company pay dividend dividend payment date dividend payment date march june september december dividend pay december treasury stock summary treasury share transaction year end december follow hare milli ons share balance january share issue stock incentive plan share balance december prefer share purchase right company prefer share purchase right outstanding attach presently trade company common share exercisable right exercisable person group acquire percent company common stock announce tender offer complete result ownership person group percent company common stock person group acquire percent company outstanding common stock merger business combination transaction right entitle holder acquirer purchase common share scheringplough market value twice exercise price right exercise price right follow acquisition person group beneficial ownership percent percent company common stock board director exchange right right own acquirer exchange ratio common share twohundredth share series junior participate prefer stock right prior acquisition person group beneficial ownership percent company common stock right redeemable right option board director right expire july early redeem exchange board director authorize reduce percent threshold refer great sum percent large percentage outstanding share common stock know company beneficially own person group affiliate associate person percent follow acquisition person group beneficial ownership percent company common stock reduction adversely affect interest holder right table content note consolidated financial statement continue insurance coverage company maintain insurance coverage deductible selfinsurance management believe adequate need current circumstance coverage reflect market condition include cost availability exist time write relationship insurance coverage selfinsurance vary accordingly result recent external event availability insurance restrictive management consider impact change continually assess good way provide insurance need future company selfinsure high proportion risk past especially relate product liability stock incentive plan term company stock incentive plan approve company shareholder million company common share grant stock option award deferred stock unit officer certain employee company december december million option defer stock unit remain available future year grant stock incentive plan option exercise price equal market price common share grant date option expire later year date grant standard option grant threeyear vest term grant prior generally oneyear vest term option grant vest long period range year defer stock unit payable equivalent number common share share distributable single installment equal annual installment generally commence year date award follow table summarize stock option activity past year current prior plan approve company shareholder weight weight weight number average number average number average exercise exercise exercise option price option price option price num ber option illion outstanding january grant exercise cancel expire outstanding december exercisable december summarize information stock option outstanding exercisable december follow stand exercisable weighted average weighted weight number remain average number average term exercise exercise exercise price range option year price option price numbe option million table content note consolidated financial statement continue company award defer stock unit total million million million respectively retirement plan postretirement benefit company define benefit pension plan cover eligible employee certain foreign country company provide postretirement health care benefit eligible retiree dependent measurement date majority plan december net pension expense compare net pension expense estimate onehalf percent reduction expect long term rate return consolidate plan asset increase pension expense approximately estimate onehalf percent reduction discount rate increase pension expense approximately december company unrecognize net actuarial loss gain loss arise primarily plan asset earn longterm expect rate return change pension discount rate gain future offset net unrecognized loss amortization loss ultimately increase annual pension expense approximately component net pension postretirement benefit expense follow pos tret ire ment alth retirement plans care benefit service cost interest cost expect return plan asset amortization net termination benefit curtailment settlement net pension postretirement benefit expense termination benefit curtailment settlement cost primarily relate matter discuss note special charge table content note consolidated financial statement continue component change benefit obligation follow post tirem ent health care retirement plan benefit benefit obligation january service cost interest cost assumption change effect exchange rate change benefit pay actuarial loss plan amendment medicare act subsidy termination benefit curtailment settlement benefit obligation december benefit obligation fund plan benefit obligation fund plan termination benefit curtailment settlement cost primarily relate matter discuss note special charge component change plan asset follow post tirem ent health care retirement plan benefit fair value plan asset primarily stock bond january actual gain loss plan asset contribution effect exchange rate change benefit pay fair value plan asset december plan asset overfunde plan plan asset underfunde plan addition plan asset indicate december security respectively hold nonqualified trust designate provide pension benefit certain underfunde plan december accumulate benefit obligation retirement plan respectively aggregate accumulate benefit obligation fair value plan asset retirement plan accumulate benefit obligation excess plan asset respectively december respectively december table content note consolidated financial statement continue contribution retirement plan postretirement health care benefit currently estimate approximately follow benefit payment reflect expect future service appropriate expect pay postret irement retirement health care plans benefit year expect benefit payment reduce expect subsidy payment medicare act respectively follow reconciliation fund status plan company balance sheet post tirem ent health care retirement plan benefit benefit obligation excess plan asset unrecognize net transition asset unrecognize prior service cost unrecognize net actuarial loss net asset december amount recognize balance sheet consist pos tret irem ent health care retirement plan benefit prepay benefit cost accrue benefit cost intangible asset accumulate comprehensive income net asset december december company additional minimum pension liability respectively primarily relate domestic retirement plan result adjustment accumulate comprehensive income net tax respectively table content note consolidated financial statement continue consolidated weightedaverage assumption determine benefit obligation december post reti reme retirement health care plan benefit discount rate rate increase future compensation consolidated weightedaverage assumption determine net cost year end december post reti reme retirement health care plan benefit discount rate longterm expect rate return plan asset rate increase future compensation longterm expect rate return plan asset derive proportionally return assumption determine major asset class principally equities fix income real estate return expectation asset class base largely assumption economic growth inflation support longterm historical data weightedaverage assume health care cost inflation rate postretirement measurement purpose percent trend percent percent increase assume health care cost trend rate increase combined postretirement service interest cost post retirement benefit obligation percent decrease assume health care cost trend rate decrease combined postretirement service interest cost postretirement benefit obligation accordance fasb staff position accounting disclosure requirement relate medicare prescription drug improvement modernization act medicare act company begin account effect federal subsidy medicare act quarter result company accumulate benefit obligation postretirement benefit reduce company net postretirement benefit expense reduce reduction postretirement benefit expense consist reduction service cost interest cost net amortization respectively plan asset fair value asset allocation consolidated retirement plan december target allocation follow rcent age plan asset target december allocation asset category equity security debt security real estate total table content note consolidated financial statement continue asset allocation postretirement health care benefit trust december target allocation follow rcent age plan asset target december allocation asset category equity security debt security total company investment relate plan broadly diversify consist primarily equity fix income security objective generate longterm investment return consistent acceptable level overall portfolio market value risk company define contribution profitshare plan cover substantially fulltime domestic employee complete year service annual contribution determine formula base company income shareholder equity participant compensation profit sharing expense total profit sharing contribution determine formula describe company long make contribution plan company begin contribution exist define contribution saving plan equal percent eligible employee earning plus matching percent eligible employee earning base employee contribution plan total company contribution plan consent decree scheringplough announce reach agreement fda consent decree resolve issue involve scheringploughs compliance current good manufacturing practice cgmp certain manufacturing facility new jersey puerto rico district court district new jersey approve enter consent decree term consent decree scheringplough agree pay total government equal installment installment pay second installment pay previously report scheringplough accrue provision consent decree fourth quarter consent decree require scheringplough complete number action include comprehensive cgmp work plan scheringplough manufacturing facility new jersey puerto revalidation finish drug product bulk active pharmaceutical ingredient manufacture facility decree schedule completion date december cgmp work plan september revalidation program bulk active pharmaceutical ingredient december revalidation program finish drug cgmp work plan contain number significant step timely satisfactory completion subject payment thousand business day deadline miss payment exceed year payment subject overall cap general timely satisfactory completion revalidation subject payment thousand business day deadline miss subject cap describe product schedule revalidation certify validate date validation schedule fda assess payment percent net domestic sale uncertified product validation certify general product schedule revalidation table content note consolidated financial statement continue consent decree certify month schedule date scheringplough cease production product certification obtain completion significant step work plan completion revalidation program subject thirdparty expert certification fdas acceptance certification consent decree provide scheringplough belief able meet deadline scheringplough right show good cause request extension deadline connection cgmp work plan revalidation program guarantee fda grant request scheringplough believe significant progress meet obligation consent decree possible scheringplough fail complete significant step revalidation prescribe deadline thirdparty expert certify completion significant step revalidation fda disagree expert certification significant step revalidation case possible fda assess payment describe scheringplough expense payment assess decree incur segment information company reportable segment prescription pharmaceutical consumer health care animal health segment sale profit datum follow consistent company current management reporting structure prescription pharmaceutical segment discover develop manufacture market human pharmaceutical product consumer health care segment develop manufacture market otc foot care sun care product animal health segment discover develop manufacture market animal health product net sale segment ear nde dece mbe prescription pharmaceutical consumer health care animal health consolidate net sale profit segment ear nde dece mber prescription pharmaceutical consumer health care animal health corporate consolidated lossprofit tax corporate include interest income expense foreign exchange gain loss headquarters expense special charge miscellaneous item accounting policy segment report describe note summary significant accounting policy corporate include special charge include employee termination cost asset impairment charge closure cost primarily related exit table content note consolidated financial statement continue small european researchanddevelopment facility note special charge additional information estimate charge relate reportable segment follow prescription pharmaceutical consumer health care animal health corporate corporate include special charge include employee termination cost provision increase litigation reserve asset impairment charge note special charge additional information estimate charge relate reportable segment follow prescription pharmaceutical consumer health care animal health corporate net sale major product prescription pharmaceutical remicade clarinexaerius nasonex pegintron temodar integrilin claritin intron rebetol subutex elocon caelyx pharmaceutical consumer health care otc include otc claritin sale respectively foot care sun care animal health consolidate net sale net sale geographic area united states europe canada latin america pacific area asia consolidate net sale table content note consolidated financial statement continue company subsidiary country outside single foreign country france italy japan account percent consolidated net sale past year net sale present geographic area company customer locate total international sale france italy japan net sale customer mckesson corporation amerisourcebergen corporation single customer mckesson corporation amerisourcebergen corporation major pharmaceutical health care product distributor account percent consolidated net sale past year longlive asset geographic location united states ireland singapore puerto rico total longlive asset show geographic location primarily property sale product comprise percent company international sale year end december follow internat ional remicade clarinex otc claritin nasonex scheringplough net sale include sale vytorin zetia market partnership merck company account joint venture equity method accounting note equity income cholesterol joint venture company disaggregate asset segment basis internal management report information present table content note consolidated financial statement continue legal environmental regulatory matter background company involve claim investigation legal proceeding company record liability contingency probable liability incur reasonably estimate company adjust liabilitie contingency reflect current good estimate probable loss minimum liability case well estimate determinable company record minimum probable range liability expect insurance recovery consider determine amount record liability environmentalrelate matter company believe loss contingency reasonably possible probable loss estimate liability record liability reasonably possible disclosure loss contingency company review status matter discuss remainder note ongoing basis time time company settle resolve matter term condition management believe good interest company resolution item discuss remainder note individually aggregate material adverse effect company result operation cash flow financial condition resolution include settlement matter type set forth remainder note particular investigation frequently involve fine penalty material financial condition cash flow result operation resolution matter involve injunctive administrative remedy adversely impact business exclusion government reimbursement program turn material adverse impact business future financial condition cash flow result operation assurance company prevail matter discuss remainder note settlement reach acceptable term include scope release provide absence injunctive administrative remedy adversely impact business exclusion government reimbursement program amount exceed amount reserve acceptable settlement reach assurance investigation litigation commence raise similar issue potentially expose company additional material liability outcome matter discuss investigation include commencement civil andor criminal proceeding involve imposition substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program total liability reserve reflect estimate case investigation estimate minimum liability final settlement adjudication matter possibly materially exceed liability record financial statement material adverse impact company financial condition cash flow operation company predict timing resolution matter outcome matter discuss remainder note record liability contingency december relate expense incur year end december material opinion management base advice legal counsel ultimate outcome matter matter discuss remainder note material impact company result operation cash flow financial condition table content note consolidated financial statement continue company increase litigation contingent liability result investigation attorney office district massachusetts attorneys office eastern district pennsylvania note pennsylvania investigation settle payment company previously record liability approximately relate massachusetts investigation reasonably possible settlement massachusetts investigation involve amount materially excess accrual material adverse impact company financial condition cash flow operation require gaap company reasonably estimate potential final resolution company recognize estimate minimum liability massachusetts investigation patent matter scholl freeze away patent july orasure technology file action district court eastern district pennsylvania allege patent infringement scheringplough healthcare product sale scholl freeze away wart removal product complaint seek permanent injunction unspecified damage include treble damage freeze away product launch march net sale product total approximately investigation pennsylvania investigation july scheringplough corporation department justice attorney office eastern district pennsylvania announce settlement previously disclose investigation office settlement schering sale corporation indirect wholly own subsidiary scheringplough corporation plead guilty single federal criminal charge concern payment manage care customer connection settlement aggregate settlement fine damage scheringplough corporation credit previously pay additional medicaid rebate leave net settlement plus interest pay schering sale corporation exclude participate federal health care program settlement affect ability scheringplough corporation participate program scheringplough corporation enter fiveyear corporate integrity agreement office inspector general department health human services scheringplough corporation agree implement specific measure promote compliance regulation issue marketing failure comply result financial penalty company predict impact settlement outstanding investigation massachusetts investigation attorney office district massachusetts investigate broad range company sale marketing clinical trial practice program warrick pharmaceuticals warrick companys generic subsidiary scheringplough disclose connection investigation schere corporation wholly own significant operating subsidiary scheringplough receive letter boston target letter office advise schering corporation include subsidiary division target federal criminal investigation respect area provide remuneration drug sample clinical trial grant item service value manage care organization physician induce purchase schering pharmaceutical product sale misbrande unapproved drug company understand mean drug promote indication approval fda obtain socalle offlabel use table content note consolidated financial statement continue submit false pharmaceutical pricing information government purpose calculate rebate require pay medicaid program fail include price product manufacture sell private label arrangement manage care customer price free nominally price good provide customer induce purchase schering product document destruction obstruction justice relate government investigation target define department justice guideline person prosecutor grand jury substantial evidence link commission crime judgment prosecutor putative defendant attorney manual section company implement certain change sale marketing clinical trial practice continue review practice ensure compliance relevant law regulation company cooperate investigation information prior increase liability reserve financial statement include relation investigation litigation charge note special charge additional information reserve potential impact outcome investigation background section note company previously record liability approximately relate investigation reasonably possible settlement investigation involve amount materially excess accrual material adverse impact company financial condition cash flow operation require gaap company reasonably estimate potential final resolution company recognize estimate minimum liability nitrodur investigation august company receive civil investigative subpoena issue office inspector general department health human service seek document concern company classification nitrodur medicaid rebate purpose company use nominal pricing bundle product sale company cooperate investigation appear subpoena number address pharmaceutical company concern inquiry issue relate payment government rebate pricing matter awp investigation company continue respond investigation department health human services department justice certain state industry company practice average wholesale price awp investigation include department justice review merit federal action file private entity behalf district court southern district florida investigation attorney office district massachusett inter alia awp set pharmaceutical company certain drug improperly exceed average price pay dispenser consequence result unlawful inflation certain government drug reimbursement base awp march company receive subpoena massachusetts attorney general office seek document concern use awp pricing andor marketing practice company respond subpoenas attorney general california concern matters company cooperate investigation outcome investigation include imposition substantial fine penalty injunctive administrative remedy prescription access litigation december prescription access litigation project pal bostonbased group form litigate drug company file class action suit federal court massachusetts company september consolidated complaint file court result coordination multidistrict litigation panel federal court awp case country consolidate complaint allege company warrick pharmaceutical table content note consolidated financial statement continue company generic subsidiary conspire provider defraud consumer report fraudulently high awps prescription medication reimburse medicare thirdparty payer complaint seek declaratory judgment unspecified damage include treble damage include litigation describe prior paragraph lawsuit allege company warrick report inflated awps prescription pharmaceutical cause state federal entity thirdparty payer excess reimbursement provider action allege company warrick fail report accurate price medicaid rebate program underpaid rebate state case file state attorney general seek recover behalf citizen state entity locate state excess payment result inflated awps action begin october bring state attorney general private plaintiff nonprofit organization employee benefit fund allege violation federal state law include fraud antitrust racketeer influence corrupt organization act rico claim quarter company warrick group company accelerate discovery track proceeding addition warrick company defendant number lawsuit state court action generally bring states andor political subdivision seek unspecified damage include treble punitive damage security class action litigation february company state press release fda conduct inspection company manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current good manufacturing practice primarily relate production process control procedure day february lawsuit file district court district new jersey company certain name officer allege violation section securities exchange act rule promulgate thereunder additional lawsuit tenor follow complaint consolidate action district court district new jersey lead plaintiff florida state board administration appoint court july october consolidated amend complaint file allege violation describe second sentence paragraph purport represent class shareholder purchase share company stock february complaint seek compensatory damage behalf class company motion dismiss consolidated amend complaint deny october court certify shareholder class discovery ongoing addition lawsuit describe immediately precede paragraph lawsuit file district court district new jersey lawsuit file new jersey state court company nominal defendant certain officer director director seek damage behalf company include disgorgement trading profit defendant allegedly obtain basis material nonpublic information complaint lawsuit relate issue describe company february press release allege failure disclose material information breach fiduciary duty director federal court lawsuit include allegation relate investigation attorney office eastern district pennsylvania district massachusetts ftcs administrative proceeding company lawsuit state texas warrick companys generic subsidiary attorney investigation ftc proceeding describe texas litigation described previously file lawsuit shareholder derivative action purport assert claim behalf company demand board director decision company pursue claim august plaintiffs new jersey state court shareholder derivative action move dismiss voluntarily complaint action motion grant shareholder derivative action pende district court district new jersey consolidate action table content note consolidated financial statement continue early stage january company receive demand letter date december law firm involve derivative action describe behalf shareholder involve derivative action demand board director bring claim behalf company base allegation substantially similar allege derivative action january board director adopt board resolution establish evaluation committee consist director investigate review analyze fact circumstance surround allegation demand letter consolidate amend derivative action complaint describe reserve board authority discretion exercise business judgment respect proper disposition demand committee engage independent outside counsel advise issue report finding investigation independent director board late october report determine shareholder demand refuse find liability officer director november board adopt recommendation evaluation committee company defendant number purport nationwide state class action lawsuit plaintiff seek refund purchase price laxative phenylpropanolaminecontaine coughcold remedy ppa product purchase pharmaceutical manufacturer codefendant lawsuit general plaintiff claim purchase pay product know certain defect medical risk attendant use litigation claim relate company ppa product court national class action suit state class action suit deny certification dismiss suit similar application deny class certification new jersey remain statewide class action suit involve company grant september approximately individual lawsuit relate laxative product ppa product recall albuterolvancerilvancenase inhaler pende company seek recovery personal injury death number lawsuit punitive damage claim litigation file district court new jersey allege company richard jay kogan company employee saving plan plan administrator current director certain corporate officer breach fiduciary obligation certain participant plan complaint seek damage loss allegedly suffer plan complaint dismiss june plaintiff appeal pende lawsuit file new jersey superior court chancery division union county allege breach fiduciary duty outside director relate company receipt boston target letter describe investigation section note dismiss september consent party antitrust ftc matter kdur kdur scheringploughs longacte potassium chloride product supplement cardiac patient scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle relate generic version kdur lederle upsher smith file abbreviate new drug application andas april ftc start administrative proceeding scheringplough upshersmith lederle complaint allege anticompetitive effect settlement june administrative law judge oversee case issue decision patent litigation settlement comply law respect dismiss claim company ftc staff appeal decision commission december commission issue opinion reverse decision rule settlement violate antitrust law commission issue cease desist order impose injunctive restraint opinion file march federal court appeal set aside commission rule vacate cease desist order table content note consolidated financial statement continue follow commencement ftc administrative proceeding allege class action suit file federal state court behalf direct indirect purchaser kdur scheringplough upshersmith lederle suit allege essentially fact claim violation federal state antitrust law state statutory andor common law cause action suit seek unspecified damage discovery ongoing sec inquiry relate litigation september sec company announce settlement sec enforcement proceeding company richard jay kogan chairman chief executive officer meeting hold investor week september communication admit deny allegation company agree commit future violation regulation relate security law pay civil penalty million kogan pay civil penalty thousand september lawsuit file new jersey superior court union county richard jay kogan company outside director allege breach fiduciary duty fraud deceit negligent misrepresentation relate alleged disclosure meeting mention company remove case federal court case remand state court company file motion dismiss matter emea pharmacovigilance matter pharmacovigilance inspection official british french medicine agency conduct request european agency evaluation medicinal product emea deficiency report process identify scheringplough continues work action plan rectify deficiency provide regular update emea company know action emea national authority response finding possible action include inspection demand improvement report system criminal sanction company andor responsible individual change condition marketing authorization company product biopharma contract dispute biopharma srl file claim civil court rome july docket chamber certain scheringplough subsidiary matter relate certain contract date november distribution supply agreement biopharma scheringplough subsidiary distribution scheringplough generic product manufacture biopharma hospital pharmacist france july letter agreement biopharma scheringplough subsidiary medipha sante appoint medipha distribute product france biopharma allege scheringplough fulfill duty contract tax matter october irs auditor assert report company liable additional tax tax year report allege interest rate swap company enter unrelated party recharacterize loan affiliate company april company receive formal notice deficiency statutory notice irs assert additional federal income tax company receive bill relate matter irs september payment income tax interest september company file refund claim tax interest irs december company notify february refund claim deny irs company believe comply applicable rule regulation intend file suit refund tax interest company tax reserve adequate cover abovementione payment table content note consolidated financial statement continue environmental company responsibility environmental cleanup state local federal law include comprehensive environmental response compensation liability act commonly know superfund superfund site equivalent site state law company allege potentially responsible party prp site separately disclose company believe remote time material liability relation site company estimate obligation cleanup cost superfund site base information obtain federal environmental protection agency epa equivalent state agency andor study prepare independent engineer probable cost pay prps company record liability environmental assessment andor cleanup probable loss incur reasonably estimate table content report independent register public accounting firm board director shareholder scheringplough corporation audit accompany consolidated balance sheet scheringplough corporation subsidiary company december relate consolidated statement operation shareholder equity cash flow year period end december audits include financial statement schedule list item financial statement financial statement schedule responsibility company management responsibility express opinion financial statement financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position scheringplough corporation subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion financial statement schedule consider relation basic consolidated financial statement take present fairly material respect information set forth audit accordance standard public company accounting oversight board united states effectiveness company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission report date march express unqualified opinion management assessment effectiveness company internal control financial report unqualified opinion effectiveness company internal control financial reporting deloitte touche llp parsippany new jersey march table content scheringplough corporation subsidiary quarterly datum unaudite thre onth end march june september december ollar illion share fig ure net sale cost sale gross profit sell general administrative research development income expense net special charge equity incomeloss cholesterol joint venture lossincome income taxis income tax benefitexpense net lossincome dividend prefer share net lossincome available common shareholder dilute lossearning common share basic lossearning common share dividend common share common share price high low average share outstanding diluted eps million average share outstanding basic eps million special charge footnote note consolidated financial statement additional information relate special charge company common share list principally trade new york stock exchange approximate number holder record common share january item change disagreement accountant account financial disclosure applicable item control procedure management include chief executive officer chief financial officer evaluate company disclosure control procedure end period cover conclude company disclosure control procedure effective conclude change companys internal control financial reporting occur company recent fiscal quarter materially affect reasonably likely materially affect company internal control financial reporting table content management report internal control financial reporting management scheringplough corporation responsible establish maintain adequate internal control financial reporting schering plough internal control system design provide reasonable assurance company management board director preparation fair presentation publish financial statement internal control system matter design inherent limitation system determine effective provide reasonable assurance respect financial statement preparation presentation scheringplough management assess effectiveness company internal control financial reporting december make assessment management criterion set forth committee sponsor organization treadway commission coso internal control integrate framework base assessment management believe december company internal control financial reporting effective base criterion scheringplough independent auditor deloitte touche llp issue attestation report management assessment company internal control financial reporting report follow table content report independent register public accounting firm board director shareholder scheringplough corporation audit management assessment include accompany management report internal control financial reporting schering plough corporation subsidiary company maintain effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion management assessment opinion effectiveness company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting evaluate management assessment testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion management assessment company maintain effective internal control financial reporting december fairly state material respect base criterion establish internal control integrate framework issue committee sponsor organization treadway commission opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission table content audit accordance standard public company accounting oversight board united states consolidated financial statement financial statement schedule year end december company report date march express unqualified opinion financial statement financial statement schedule deloitte touche llp parsippany new jersey march table content iii item director executive officer registrant information concern director nominee director set forth caption proposal election director stock ownership company proxy statement annual meeting shareholder april incorporate reference information require executive officer include file caption executive officer registrant company board director determine company audit committee financial expert serve audit committee financial expert arthur weinbach independent define new york stock exchange list standard restrictive scheringplough board independence standard find scheringplough corporate governance guideline available web site include proxy statement require rule securities exchange act amend company adopt standard global business practice applicable employee include chief executive officer chief financial officer controller standard global business practice incorporate reference exhibit write copy standard global business practice director code conduct ethic provide charge write corporate secretary scheringplough corporation gallop hill road mail stop kenilworth new jersey document available scheringplough web site wwwscheringploughcom investor relation corporate governance code conduct item executive compensation executive compensation information set forth caption executive compensation company proxy statement annual meeting shareholder april incorporate reference item security ownership certain beneficial owner management relate stockholder matter information concern security ownership certain beneficial owner management set forth caption stock ownership company proxy statement annual meeting shareholder april incorporate reference equity compensation plan information follow information relate plan equity security company issue employee director company plan equity security issue nonemployee stock incentive plan predecessor plan certain stock option transferable family member employeeoptionee relate trust table content column olumn column number security remain available weightedaverage future issuance equity number security issue exercise price compensation plan exercise outstanding outstanding option exclude security reflect plan category option warrant right warrant right column equity compe nsation plan approve security holder stock incentive plan predecessor plan equity compensation plan approve security holder director stock award plan scheringplough ireland share purchase scheme nonplan inducement award approve security holder restrict share total plan provide annual grant share common stock nonemployee director director defer award stock unit pay share common stock deferral period end plan permit employee reside ireland enjoy tax advantage christmas bonus pay pass trustee trustee purchase share common stock open market allocate share employee account irish pound employee defer year employee sell withdraw share allocate account year represents restrict share award pursuant restrict share agreement outside equity compensation plan adopt company hassan award restricted share commencement employment april cox award restricted share commencement employment award restrict share vest anniversary award date nonplan award authorize compensation committee board approve stockholders company item certain relationship relate transaction information concern certain relationship relate transaction set forth caption certain transaction companys proxy statement annual meeting shareholder april incorporate reference item principal accountant fee service information concern principal accountant fee service set forth caption proposal ratification designation independent register public accountant company proxy statement annual meeting shareholder april incorporate reference table content item